

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Lancet, The

396, 467-478

DOI: [10.1016/s0140-6736\(20\)31604-4](https://doi.org/10.1016/s0140-6736(20)31604-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Public preference for COVID-19 vaccines in China: A discrete choice experiment. <i>Health Expectations</i> , 2020, 23, 1543-1578.	1.1	108
2	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. <i>Pharmaceutics</i> , 2020, 12, 945.	2.0	14
3	Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. <i>Frontiers in Immunology</i> , 2020, 11, 561851.	2.2	4
4	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. <i>British Journal of Biomedical Science</i> , 2020, 77, 168-184.	1.2	12
5	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	204
6	The complexities of SARS-CoV-2 serology. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1350-1351.	4.6	42
7	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020, 183, 169-184.e13.	13.5	446
8	COVID-19 Vaccine: A comprehensive status report. <i>Virus Research</i> , 2020, 288, 198114.	1.1	628
9	What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. <i>Vaccine: X</i> , 2020, 6, 100076.	0.9	62
10	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. <i>ESMO Open</i> , 2020, 5, e000947.	2.0	63
11	COVID-19 in the Pediatric Population—Review and Current Evidence. <i>Current Infectious Disease Reports</i> , 2020, 22, 29.	1.3	32
12	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. <i>Frontiers in Pharmacology</i> , 2020, 11, 1224.	1.6	30
13	Leveraging the advances in HIV for COVID-19. <i>Lancet</i> , The, 2020, 396, 943-944.	6.3	8
14	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020, 183, 1024-1042.e21.	13.5	1,195
15	Challenges in the Development of a Vaccine Against COVID-19. <i>Engineering</i> , 2020, 6, 1067-1069.	3.2	0
16	Enhancing sensitivity of lateral flow assay with application to SARS-CoV-2. <i>Applied Physics Letters</i> , 2020, 117, 120601.	1.5	34
17	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2020, 11, 583252.	1.5	18
18	All Surfaces Are Not Equal in Contact Transmission of SARS-CoV-2. <i>Matter</i> , 2020, 3, 1433-1441.	5.0	49

#	ARTICLE	IF	CITATIONS
19	Coronavirus disease-19 vaccine development utilizing promising technology. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 351-358.	1.5	4
20	Correlations between Meteorological Indicators, Air Quality and the COVID-19 Pandemic in 12 Cities across China. <i>Journal of Environmental Health Science &amp; Engineering</i> , 2020, 18, 1491-1498.	1.4	13
21	Strategies and Advances in Combating COVID-19 in China. <i>Engineering</i> , 2020, 6, 1076-1084.	3.2	16
22	Sex-Based Vaccine Response in the Context of COVID-19. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, 405-408.	0.2	44
23	The Coronavirus Disease 2019 pandemic: how does it spread and how do we stop it?. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 328-335.	1.5	7
24	Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. <i>Vaccines</i> , 2020, 8, 574.	2.1	40
25	Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection. <i>Vaccines</i> , 2020, 8, 584.	2.1	48
26	COVID-19 vaccinations in patients with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 965-966.	3.7	12
27	The transmission modes and sources of COVID-19: A systematic review. <i>International Journal of Surgery Open</i> , 2020, 26, 125-136.	0.2	84
28	COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. <i>ACS Nano</i> , 2020, 14, 12522-12537.	7.3	259
29	A systematic review of SARS-CoV-2 vaccine candidates. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 237.	7.1	427
30	&lt;p&gt;Cancer Care Management During the COVID-19 Pandemic&lt;/p&gt;. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1711-1721.	1.2	13
31	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. <i>Lancet, The</i> , 2020, 396, 1595-1606.	6.3	511
32	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <i>Immunobiology</i> , 2020, 225, 152008.	0.8	65
33	Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines. <i>Npj Vaccines</i> , 2020, 5, 88.	2.9	21
34	SARS-CoV-2 vaccines in development. <i>Nature</i> , 2020, 586, 516-527.	13.7	1,659
36	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , 2020, 140, 86-104.	1.3	33
37	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> , 2020, 183, 996-1012.e19.	13.5	1,494

#	ARTICLE	IF	CITATIONS
38	Integrated control of COVID-19 in resource-poor countries. <i>International Journal of Infectious Diseases</i> , 2020, 101, 98-101.	1.5	19
39	Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present I±-gal epitopes. <i>Vaccine</i> , 2020, 38, 6487-6499.	1.7	31
40	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. <i>Virus Research</i> , 2020, 288, 198141.	1.1	116
41	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. <i>Clinical Infectious Diseases</i> , 2021, 73, 336-340.	2.9	70
42	Encouraging results from phase 1/2 COVID-19 vaccine trials. <i>Lancet, The</i> , 2020, 396, 448-449.	6.3	46
43	Profile of SARS-CoV-2. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 635-644.	1.0	4
44	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
45	Development and Applications of Viral Vected Vaccines to Combat Zoonotic and Emerging Public Health Threats. <i>Vaccines</i> , 2020, 8, 680.	2.1	50
46	Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals. <i>Vaccines</i> , 2020, 8, 684.	2.1	11
47	Notice of addendum to Article reporting Oxford trial of ChAdOx1 nCoV-19 vaccine. <i>Lancet, The</i> , 2020, 396, e89.	6.3	2
48	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
49	Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. <i>Viruses</i> , 2020, 12, 1324.	1.5	35
50	Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. <i>Emerging Microbes and Infections</i> , 2020, 9, 2606-2618.	3.0	28
52	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	7.1	149
53	Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys. <i>Frontiers in Immunology</i> , 2020, 11, 579872.	2.2	20
54	Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 578382.	1.6	38
55	Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. <i>Food and Chemical Toxicology</i> , 2020, 146, 111805.	1.8	31
56	Current COVID-19 vaccine candidates: Implications in the Saudi population. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1743-1748.	1.2	17

#	ARTICLE	IF	CITATIONS
57	A year in our understanding of COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 146-148.	1.1	2
58	SARS coronavirus 2: from genome to infectome. <i>Respiratory Research</i> , 2020, 21, 318.	1.4	62
59	Adenovirusâ€™ Extracellular Protein Interactions and Their Impact on Innate Immune Responses by Human Mononuclear Phagocytes. <i>Viruses</i> , 2020, 12, 1351.	1.5	21
60	Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	0.9	29
61	Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity. <i>Vaccines</i> , 2020, 8, 683.	2.1	10
62	Efforts at COVID-19 Vaccine Development: Challenges and Successes. <i>Vaccines</i> , 2020, 8, 739.	2.1	98
63	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2020, 39, 723-730.	0.6	22
64	Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. <i>Frontiers in Immunology</i> , 2020, 11, 583019.	2.2	98
65	Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, , .	0.8	3
66	COVIDâ€™19 vaccines: the importance of transparency and factâ€™based education. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2107-2110.	1.1	13
67	COVID-19 spread in the UK: the end of the beginning?. <i>Lancet, The</i> , 2020, 396, 587-590.	6.3	66
68	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98
69	Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. <i>Vaccine</i> , 2020, 38, 6075-6077.	1.7	17
70	Covid-19: Where are we on immunity and vaccines?. <i>BMJ, The</i> , 2020, 370, m3096.	3.0	9
71	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24
72	Restructuring of dental education in a postâ€™COVIDâ€™19 era. <i>Oral Diseases</i> , 2022, 28, 920-921.	1.5	3
73	Cellular immune responses to covid-19. <i>BMJ, The</i> , 2020, 370, m3018.	3.0	47
74	The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. <i>Current Allergy and Asthma Reports</i> , 2020, 20, 61.	2.4	127

#	ARTICLE	IF	CITATIONS
75	Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life Sciences, 2020, 258, 118202.	2.0	43
76	Covid-19: UK agrees to "early access" deal with companies to get 90 million vaccine doses. BMJ, The, 2020, 370, m2914.	3.0	3
77	An Inactivated Virus Candidate Vaccine to Prevent COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 943.	3.8	12
78	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA - Journal of the American Medical Association, 2020, 324, 951.	3.8	671
79	Protecting the Herd: Why Pharmacists Matter in Mass Vaccination. Pharmacy (Basel, Switzerland), 2020, 8, 199.	0.6	23
80	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. MBio, 2020, 11, .	1.8	99
81	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in Immunology, 2020, 11, 579250.	2.2	72
82	Synthesis, Structure, and Function of Human Adenovirus Small Non-Coding RNAs. Viruses, 2020, 12, 1182.	1.5	13
83	Vaccines against COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 703-705.	0.6	31
85	PHARMACOLOGICAL TREATMENTS OF COVID-19 " A REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 0, , 16-22.	0.3	4
86	The Current Status of COVID-19 Vaccines. Frontiers in Genome Editing, 2020, 2, 579297.	2.7	25
87	Emerging Concepts and Technologies in Vaccine Development. Frontiers in Immunology, 2020, 11, 583077.	2.2	159
88	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
89	COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines.. Expert Review of Vaccines, 2020, 19, 937-947.	2.0	12
90	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. Frontiers in Cell and Developmental Biology, 2020, 8, 580202.	1.8	20
91	An Effective COVID-19 Vaccine Needs to Engage T Cells. Frontiers in Immunology, 2020, 11, 581807.	2.2	75
92	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	13.5	420
93	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology, 2020, 11, 585354.	2.2	384

#	ARTICLE	IF	CITATIONS
94	Viral Related Tools against SARS-CoV-2. <i>Viruses</i> , 2020, 12, 1172.	1.5	3
95	Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. <i>Immunity</i> , 2020, 53, 1095-1107.e3.	6.6	273
96	What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist. <i>Frontiers in Immunology</i> , 2020, 11, 2173.	2.2	8
97	Vaccine Against Covid-19 Disease – Present Status of Development. <i>Indian Journal of Pediatrics</i> , 2020, 87, 810-816.	0.3	38
98	Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. <i>Rheumatology International</i> , 2020, 40, 1741-1751.	1.5	34
99	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 40.	1.7	93
100	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. <i>Lancet</i> , The, 2020, 396, 887-897.	6.3	822
101	COVID-19 vaccines: early success and remaining challenges. <i>Lancet</i> , The, 2020, 396, 868-869.	6.3	29
102	Immunological considerations for COVID-19 vaccine strategies. <i>Nature Reviews Immunology</i> , 2020, 20, 615-632.	10.6	806
103	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	7.0	1,066
104	Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). <i>Military Medical Research</i> , 2020, 7, 41.	1.9	56
105	An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102934.	0.5	7
106	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1390-1400.	4.6	336
107	Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes. <i>Canadian Respiratory Journal</i> , 2020, 2020, 1-10.	0.8	47
108	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
109	In search of a vaccine against COVID-19: implications for nursing practice. <i>British Journal of Nursing</i> , 2020, 29, 948-953.	0.3	1
110	Vaccines targeting SARS-CoV-2 tested in humans. <i>Nature Medicine</i> , 2020, 26, 1336-1338.	15.2	7
111	Developing Safe and Effective Covid Vaccines – Operation Warp Speed™s Strategy and Approach. <i>New England Journal of Medicine</i> , 2020, 383, 1701-1703.	13.9	143

#	ARTICLE	IF	CITATIONS
112	Obesity: A critical risk factor in the <scp>COVID</scp>â€19 pandemic. <i>Clinical Obesity</i> , 2020, 10, e12403.	1.1	191
113	A Scalable Topical Vected Vaccine Candidate against SARS-CoV-2. <i>Vaccines</i> , 2020, 8, 472.	2.1	20
114	COVID-19 vaccines and neglected pregnancy. <i>Lancet, The</i> , 2020, 396, e22.	6.3	43
115	Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. <i>Vaccines</i> , 2020, 8, 474.	2.1	31
116	Vaccines for COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 162-192.	1.1	185
117	How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton. <i>PharmacoEconomics - Open</i> , 2020, 4, 557-561.	0.9	24
118	High-Throughput Cloning and Characterization of Emerging Adenovirus Types 70, 73, 74, and 75. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6370.	1.8	13
119	Efforts towards a <scp>COVID</scp>â€19 vaccine. <i>Environmental Microbiology</i> , 2020, 22, 4071-4084.	1.8	16
120	Case Report: A Recovered SARS CoV-2 Patient Protected From Reinfection. <i>Frontiers in Medicine</i> , 2020, 7, 564264.	1.2	10
121	Frontiers in the COVID-19 vaccines development. <i>Experimental Hematology and Oncology</i> , 2020, 9, 24.	2.0	15
122	Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery. <i>Vaccines</i> , 2020, 8, 504.	2.1	46
123	COVID-19: Second Wave or Multiple Peaks, Natural Herd Immunity or Vaccine â€ We Should be Prepared. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, 16, 718-725.	0.7	17
124	Fast-and-fit vaccines. <i>Nature Biomedical Engineering</i> , 2020, 4, 757-758.	11.6	1
125	Covid-19 vaccines: delivering protective immunity. <i>BMJ, The</i> , 2020, 371, m4838.	3.0	48
126	Development of vaccines and antivirals for combating viral pandemics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1128-1133.	11.6	66
127	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. <i>Clinical Infectious Diseases</i> , 2020, 73, 1540-1544.	2.9	15
128	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
129	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 569760.	2.2	30



#	ARTICLE	IF	CITATIONS
130	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
131	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	2.2	143
132	Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer. , 2020, 8, e001133.		12
133	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. <i>Vaccines</i> , 2020, 8, 746.	2.1	6
134	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. <i>Science Immunology</i> , 2020, 5, .	5.6	244
135	Knowledge and Attitudes on Vaccination in Southern Romanians: A Cross-Sectional Questionnaire. <i>Vaccines</i> , 2020, 8, 774.	2.1	27
136	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. <i>Journal of Infection</i> , 2020, 81, 931-936.	1.7	59
137	Colorectal Surgery in the time of Covid 19. <i>Colorectal Disease</i> , 2020, 22, 983-984.	0.7	0
138	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. <i>Science Immunology</i> , 2020, 5, .	5.6	404
139	A COVID-19 vaccine“ dare to dream. <i>British Journal of Community Nursing</i> , 2020, 25, 2-7.	0.2	4
140	Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro Enzymatic Activity Assay. <i>Frontiers in Chemistry</i> , 2020, 8, 623971.	1.8	45
141	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. <i>Vaccines</i> , 2020, 8, 649.	2.1	42
142	Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus. <i>Genomics</i> , 2020, 112, 5331-5342.	1.3	32
143	ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 “ Authors' reply. <i>Lancet, The</i> , 2020, 396, 1486-1487.	6.3	4
144	ChAdOx1 nCoV-19 vaccine for SARS-CoV-2. <i>Lancet, The</i> , 2020, 396, 1486.	6.3	4
145	ChAdOx1 nCoV-19 vaccine for SARS-CoV-2. <i>Lancet, The</i> , 2020, 396, 1485-1486.	6.3	4
146	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , 2020, 183, 1508-1519.e12.	13.5	263
147	Aging in COVID-19: Vulnerability, immunity and intervention. <i>Ageing Research Reviews</i> , 2021, 65, 101205.	5.0	601

#	ARTICLE	IF	CITATIONS
148	Who should be prioritised for COVID-19 vaccination?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1317-1321.	1.4	53
149	Supports for people with intellectual and developmental disabilities during the COVID-19 pandemic from their own perspective. <i>Research in Developmental Disabilities</i> , 2021, 108, 103813.	1.2	73
150	Covid-19.bioreproducibility.org: A web resource for <scp>SARS-CoV-2</scp>-related structural models. <i>Protein Science</i> , 2021, 30, 115-124.	3.1	15
151	Characteristics of SARS-CoV-2 and COVID-19. <i>Nature Reviews Microbiology</i> , 2021, 19, 141-154.	13.6	3,334
152	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
153	Temporary derogation from European environmental legislation for clinical trials of genetically modified organisms for coronavirus disease 2019. <i>Cytotherapy</i> , 2021, 23, 10-11.	0.3	2
154	The roles of nausea and vomiting in COVID-19: did we miss something?. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 541-546.	1.5	20
155	Modeling COVID-19 scenarios for the United States. <i>Nature Medicine</i> , 2021, 27, 94-105.	15.2	365
156	Severe acute respiratory syndrome-coronavirus spike (S) protein based vaccine candidates: State of the art and future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2183.	3.9	43
157	Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1113-1121.	1.4	4
158	Anti-COVID-19 terpenoid from marine sources: A docking, admet and molecular dynamics study. <i>Journal of Molecular Structure</i> , 2021, 1228, 129433.	1.8	44
159	COVID-19 lockdown: animal life, ecosystem and atmospheric environment. <i>Environment, Development and Sustainability</i> , 2021, 23, 8161-8178.	2.7	50
160	A promising inactivated whole-virion SARS-CoV-2 vaccine. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 2-3.	4.6	15
161	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.	13.6	126
162	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
163	COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. <i>European Journal of Pharmacology</i> , 2021, 892, 173751.	1.7	201
164	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. <i>Vaccine</i> , 2021, 39, 197-201.	1.7	67
165	COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1612-1621.	1.4	517

#	ARTICLE	IF	CITATIONS
166	Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3408-3424.	1.1	16
167	Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. <i>Journal of Medical Virology</i> , 2021, 93, 1967-1982.	2.5	15
168	Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets. <i>Cell Systems</i> , 2021, 12, 102-107.e4.	2.9	35
169	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1635-1649.	1.4	14
170	SARS-CoV-2: Targeted managements and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 16-29.	3.2	44
171	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
172	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111008.	2.5	40
173	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 187-191.	1.0	86
174	Stem cell therapy in coronavirus disease 2019: current evidence and future potential. <i>Cytotherapy</i> , 2021, 23, 471-482.	0.3	11
175	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 181-192.	4.6	1,104
176	Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis. <i>Age and Ageing</i> , 2021, 50, 284-293.	0.7	27
177	COVID-19: A review of therapeutic strategies and vaccine candidates. <i>Clinical Immunology</i> , 2021, 222, 108634.	1.4	180
178	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 168-189.	6.6	62
179	Identification and computational analysis of mutations in SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2021, 129, 104166.	3.9	14
180	Individual and community-level risk for COVID-19 mortality in the United States. <i>Nature Medicine</i> , 2021, 27, 264-269.	15.2	70
181	Spheroids and organoids as humanized 3D scaffold-free engineered tissues for SARS-CoV-2 viral infection and drug screening. <i>Artificial Organs</i> , 2021, 45, 548-558.	1.0	21
182	COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic. <i>Anaesthesia</i> , 2021, 76, 435-443.	1.8	4
183	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13

#	ARTICLE	IF	CITATIONS
184	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. <i>SLAS Discovery</i> , 2021, 26, 311-329.	1.4	4
185	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. <i>Frontiers in Molecular Biosciences</i> , 2021, 7, 585899.	1.6	12
186	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
187	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. <i>Mucosal Immunology</i> , 2021, 14, 305-316.	2.7	173
188	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
189	SARS-CoV-2 candidate vaccines – composition, mechanisms of action and stages of clinical development. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1922-1924.	2.7	23
190	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. <i>EClinicalMedicine</i> , 2021, 31, 100689.	3.2	206
191	COVID-19 and Solid Organ Transplantation: A Review Article. <i>Transplantation</i> , 2021, 105, 37-55.	0.5	241
192	COVID-19 and the second wave during autumn: preventive strategies in cardiac and thoracic surgery divisions. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2021, 53, 37-39.	0.3	1
193	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
194	COVID-19. <i>Critical Care Nursing Quarterly</i> , 2021, 44, 128-137.	0.4	17
195	The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world. <i>Lancet</i> , The, 2021, 397, 68-70.	6.3	33
196	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. <i>International Reviews of Immunology</i> , 2021, 40, 54-71.	1.5	10
197	Is there a role for childhood vaccination against COVID-19?. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 9-16.	1.1	38
198	T cell immunobiology and cytokine storm of COVID-19. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12989.	1.3	77
199	Repurposed Drugs, Molecular Vaccines, Immune Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. <i>Advanced Therapeutics</i> , 2021, 4, 2000172.	1.6	24
200	N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 1732-1738.	2.5	12
201	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2168.	3.9	28

#	ARTICLE	IF	CITATIONS
202	Immune response and possible therapeutics in COVID-19. RSC Advances, 2021, 11, 960-977.	1.7	7
203	An update on coronavirus disease-19 vaccines. Journal of Medical Evidence, 2021, 2, 24.	0.2	2
204	Fears and Hopes. , 2021, , 1-24.		0
205	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Frontiers in Immunology, 2020, 11, 607583.	2.2	12
206	Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering. Computational and Structural Biotechnology Journal, 2021, 19, 518-529.	1.9	19
207	Role of Bioinformatics in Subunit Vaccine Design. , 2021, , 425-439.		1
208	Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences, 2021, 3, 22-27.	0.1	12
209	Respiratory viral infections in the elderly. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662199505.	1.0	39
210	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerging Microbes and Infections, 2021, 10, 1589-1597.	3.0	41
211	Vaccination in old age: Challenges and promises. , 2021, , 129-153.		1
212	Application of Nanotechnology in the COVID-19 Pandemic. International Journal of Nanomedicine, 2021, Volume 16, 623-649.	3.3	60
213	Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. Immune Network, 2021, 21, e29.	1.6	14
214	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerging Microbes and Infections, 2021, 10, 342-355.	3.0	37
215	A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. Journal of Postgraduate Medicine, 2021, 67, 134-138.	0.2	1
216	The role and uses of antibodies in COVID-19 infections: a living review. Oxford Open Immunology, 2021, 2, iqab003.	1.2	17
217	An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 2021, 9, 97.	2.1	117
218	Decline in neutralising antibody responses, but sustained T cell immunity, in COVID-19 patients at 7 months post-infection. Clinical and Translational Immunology, 2021, 10, e1319.	1.7	34
219	COVID-19 vaccines: where we stand and challenges ahead. Cell Death and Differentiation, 2021, 28, 626-639.	5.0	626

#	ARTICLE	IF	CITATIONS
220	Survey of Adverse Events After The First Dose of The ChAdOx1 nCoV-19 Vaccine: A Single-Center Experience in Korea. <i>Infection and Chemotherapy</i> , 2021, 53, 557.	1.0	8
221	Stapled <sc>ACE2</sc> peptidomimetics designed to target the <sc>SARS-CoV-2</sc> spike protein do not prevent virus internalization. <i>Peptide Science</i> , 2021, 113, e24217.	1.0	33
223	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1-19.		0
224	Should people with severe mental illness be prioritized for the COVID-19 vaccination?. <i>International Journal of Biological Sciences</i> , 2021, 17, 1443-1445.	2.6	5
225	Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. <i>Brain Communications</i> , 2021, 3, fcab169.	1.5	48
226	A Study of COVID-19 Vaccine (COVISHIELD) Pharmacovigilance in Primary Healthcare Workers in Punjab, India. <i>AMEI S Current Trends in Diagnosis &amp; Treatment</i> , 2021, 5, 6-11.	0.1	1
227	COVID-19 Vaccine: Critical Questions with Complicated Answers. <i>Biomolecules and Therapeutics</i> , 2021, 29, 1-10.	1.1	40
228	COVID-19: Characteristics and Therapeutics. <i>Cells</i> , 2021, 10, 206.	1.8	177
229	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. <i>Open Life Sciences</i> , 2021, 16, 558-570.	0.6	8
233	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1249-1266.		0
234	COVID-19: An overview and a clinical update. <i>World Journal of Clinical Cases</i> , 2021, 9, 8-23.	0.3	38
235	The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. <i>Immunotherapy Advances</i> , 2021, 1, Itab019.	1.2	4
236	HIV vaccinology: 2021 update. <i>Seminars in Immunology</i> , 2021, 51, 101470.	2.7	31
237	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	5.3	134
238	A COVID-19 Vaccine: Big Strides Come with Big Challenges. <i>Vaccines</i> , 2021, 9, 39.	2.1	78
239	More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation. <i>Viruses</i> , 2021, 13, 217.	1.5	13
240	Acute treatment with monoclonal antibodies: their design and their use. <i>Microbiology Australia</i> , 2021, 42, 39.	0.1	0
241	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110214.	0.7	29

#	ARTICLE	IF	CITATIONS
242	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e297.	1.7	90
243	SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 541.	5.8	66
244	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. <i>Clinical and Translational Immunology</i> , 2021, 10, e1260.	1.7	13
245	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	6.0	88
247	A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 143.	1.5	16
248	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. <i>Annual Review of Microbiology</i> , 2021, 75, 19-47.	2.9	52
249	Rapid whole-blood assay to detect SARS-CoV-2-specific memory T cell immunity following a single dose of AstraZeneca ChAdOx1 COVID-19 vaccine. <i>Clinical and Translational Immunology</i> , 2021, 10, e1326.	1.7	11
251	Antibodies, epicenter of SARS-CoV-2 immunology. <i>Cell Death and Differentiation</i> , 2021, 28, 821-824.	5.0	9
252	Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e10725.	0.7	9
253	Potential of Immune-Related Therapy in COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 609212.	1.6	3
254	The Worldwide Effort to Develop Vaccines for COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 215-223.	0.8	3
255	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
256	The evolutionary dynamics of endemic human coronaviruses. <i>Virus Evolution</i> , 2021, 7, veab020.	2.2	40
257	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000063.	1.7	5
258	COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 526.	1.1	57
259	The 2020 race towards SARS-CoV-2 specific vaccines. <i>Theranostics</i> , 2021, 11, 1690-1702.	4.6	71
260	Translating viral vaccines into immunity. <i>Science</i> , 2021, 371, 460-461.	6.0	2
261	Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces. <i>International Journal of Biological Sciences</i> , 2021, 17, 1461-1468.	2.6	37

#	ARTICLE	IF	CITATIONS
262	Recent biotechnological advances as potential intervention strategies against COVID-19. <i>3 Biotech</i> , 2021, 11, 41.	1.1	10
264	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. <i>PLoS Pathogens</i> , 2021, 17, e1009161.	2.1	62
266	Vaccine responses in ageing and chronic viral infection. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	3
268	Management of COVID-19 Infection During Pregnancy, Labor, and Puerperium. , 2021, , 63-89.		1
269	Vaccinology in the postâˆ“COVID-19 era. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	62
270	The role of pseudotype neutralization assays in understanding SARS CoV-2. <i>Oxford Open Immunology</i> , 2021, 2, iqab005.	1.2	20
271	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	0.4	3
272	Attitude and Willingness of Chinese Adults with Rheumatic Diseases to Receive COVID-19 Vaccination. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
273	A review on human body fluids for the diagnosis of viral infections: scope for rapid detection of COVID-19. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 31-42.	1.5	18
274	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 36.	2.1	41
275	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
276	Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 151-161.	1.1	49
277	The Vaccine Supply Chain: A Call for Resilience Analytics to Support COVID-19 Vaccine Production and Distribution. <i>Risk, Systems and Decisions</i> , 2021, , 389-437.	0.5	21
278	Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing. <i>International Journal of Molecular Sciences</i> , 2021, 22, 477.	1.8	7
279	Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. <i>Communications Biology</i> , 2021, 4, 267.	2.0	25
280	COVID-19 vaccination in the UK: is it time to celebrate?. <i>British Journal of Community Nursing</i> , 2021, 26, 70-75.	0.2	0
282	Vaccines for COVID-19 - state of the art. <i>Revista Brasileira De Saude Materno Infantil</i> , 2021, 21, 13-19.	0.2	22
283	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. <i>Biological Procedures Online</i> , 2021, 23, 5.	1.4	20



#	ARTICLE	IF	CITATIONS
284	Ten commonly asked questions about Covid-19 and lessons learned from Thailand. <i>Journal of Health Research</i> , 2021, 35, 329-344.	0.4	7
285	Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. <i>Scientific Reports</i> , 2021, 11, 4741.	1.6	89
286	COVID-19 vaccines: implementation, limitations and opportunities. <i>Global Health &amp; Medicine</i> , 2021, 3, 1-5.	0.6	28
288	Promoting versatile vaccine development for emerging pandemics. <i>Npj Vaccines</i> , 2021, 6, 26.	2.9	26
289	A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach. <i>Frontiers in Immunology</i> , 2021, 12, 598778.	2.2	14
290	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 776.	5.8	65
292	The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. <i>Drugs in Context</i> , 2021, 10, 1-10.	1.0	77
293	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. <i>RMD Open</i> , 2021, 7, e001594.	1.8	59
294	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
295	Integrated vaccination and physical distancing interventions to prevent future COVID-19 waves in Chinese cities. <i>Nature Human Behaviour</i> , 2021, 5, 695-705.	6.2	111
296	Next-generation COVID-19 vaccines: here come the proteins. <i>Lancet, The</i> , 2021, 397, 643-645.	6.3	9
297	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e22483.	1.2	2
298	Biosecurity risks associated with vaccine platform technologies. <i>Vaccine</i> , 2022, 40, 2514-2523.	1.7	9
300	Viral vector platforms within the gene therapy landscape. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 53.	7.1	514
301	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. <i>PLoS Biology</i> , 2021, 19, e3001091.	2.6	163
302	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. <i>FASEB Journal</i> , 2021, 35, e21409.	0.2	71
304	Omics-Driven Biotechnology for Industrial Applications. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 613307.	2.0	49
305	Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. <i>Nature Human Behaviour</i> , 2021, 5, 337-348.	6.2	1,002

#	ARTICLE	IF	CITATIONS
306	Coronavirus (SARS-CoV-2): a systematic review for potential vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-18.	1.4	11
307	History in the making. <i>Oral Surgery</i> , 2021, 14, 3-4.	0.1	0
308	Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam. <i>Emerging Infectious Diseases</i> , 2021, 27, 663-666.	2.0	14
310	Codon Usage and Adenovirus Fitness: Implications for Vaccine Development. <i>Frontiers in Microbiology</i> , 2021, 12, 633946.	1.5	10
311	Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India. <i>Frontiers in Genetics</i> , 2021, 12, 637362.	1.1	5
312	Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. <i>Journal of Virology</i> , 2021, 95, .	1.5	48
313	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 682-694.	6.3	235
314	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. <i>Mayo Clinic Proceedings</i> , 2021, 96, 446-463.	1.4	62
315	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. <i>Journal of Hematology and Oncology</i> , 2021, 14, 38.	6.9	87
316	COVID-19 vaccine candidates: A review. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 58-63.	0.1	1
318	What place does nurse-led research have in the COVID-19 pandemic?. <i>International Nursing Review</i> , 2021, 68, 214-218.	1.5	13
319	Vaccines - safety in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 76, 23-40.	1.4	39
320	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200950.	1.5	22
321	Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 173-187.	1.2	23
322	Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea. <i>Journal of Clinical Medicine</i> , 2021, 10, 591.	1.0	64
323	Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2417.	1.8	17
325	COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8.	1.5	21
326	Viral Vectors for COVID-19 Vaccine Development. <i>Viruses</i> , 2021, 13, 317.	1.5	65

#	ARTICLE	IF	CITATIONS
327	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. <i>Nature Communications</i> , 2021, 12, 1018.	5.8	82
328	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43
329	Key facts about the COVID-19 vaccination programme in the UK. <i>Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals</i> , 2021, 13, 56-58.	0.0	1
331	Development and deployment of COVID-19 vaccines for those most vulnerable. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	60
332	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. <i>Npj Vaccines</i> , 2021, 6, 28.	2.9	507
333	DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. <i>Scientific Reports</i> , 2021, 11, 3125.	1.6	17
334	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. <i>Frontiers in Immunology</i> , 2020, 11, 599568.	2.2	16
335	Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. <i>MBio</i> , 2021, 12, .	1.8	64
336	Optical Detection of CoV-SARS-2 Viral Proteins to Sub-Picomolar Concentrations. <i>ACS Omega</i> , 2021, 6, 6404-6413.	1.6	38
337	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
338	An overview of Covid-19 pandemic: immunology and pharmacology. <i>Journal of Immunoassay and Immunochemistry</i> , 2021, 42, 493-512.	0.5	1
339	SARS-CoV-2 virus: Vaccines in development. <i>Fundamental Research</i> , 2021, 1, 131-138.	1.6	12
341	An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo. <i>Vaccines</i> , 2021, 9, 244.	2.1	15
343	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. <i>JCI Insight</i> , 2021, 6, .	2.3	39
345	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 104, 441-451.	1.5	14
346	Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 427-439.	0.9	175
347	Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. <i>Frontiers in Immunology</i> , 2021, 12, 637982.	2.2	9
348	The potential neurological effect of the COVID-19 vaccines: A review. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 3-12.	1.0	85

#	ARTICLE	IF	CITATIONS
349	An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. <i>Pharmaceutics</i> , 2021, 13, 455.	2.0	55
350	Can a COVID-19 vaccine live up to Americans'™ expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions. <i>Social Science and Medicine</i> , 2021, 272, 113642.	1.8	109
352	Vaccines and drugs under clinical trials for prevention and treatment of COVID-19. <i>VirusDisease</i> , 2021, 32, 13-19.	1.0	6
353	Aging researchers in early stages (ARIES): a model for career development collaboration of researchers in aging. <i>Quality in Ageing and Older Adults</i> , 2021, 22, 75-80.	0.4	0
354	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
355	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. <i>Med</i> , 2021, 2, 243-262.e8.	2.2	62
356	Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?. <i>Lancet, The</i> , 2021, 397, 879-880.	6.3	29
357	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
358	Development of COVID-19 vaccines utilizing gene therapy technology. <i>International Immunology</i> , 2021, 33, 521-527.	1.8	19
359	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. <i>Science Advances</i> , 2021, 7, .	4.7	80
360	Potential neutralizing antibodies discovered for novel corona virus using machine learning. <i>Scientific Reports</i> , 2021, 11, 5261.	1.6	62
361	A comparative online survey on the intention to get COVID-19 vaccine between Greek and Cypriot healthcare personnel: is the country a predictor?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2397-2404.	1.4	23
362	Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike. <i>ACS Central Science</i> , 2021, 7, 586-593.	5.3	68
363	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
365	Binding of SARS-CoV-2/SARS-CoV spike protein with human ACE2 receptor. <i>Journal of Physics Communications</i> , 2021, 5, 035010.	0.5	6
366	Risk of SARS-CoV-2 reinfection after natural infection. <i>Lancet, The</i> , 2021, 397, 1161-1163.	6.3	53
367	COVID-19 vaccines: rapid development, implications, challenges and future prospects. <i>Human Cell</i> , 2021, 34, 711-733.	1.2	227
368	SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. <i>Pediatric Transplantation</i> , 2021, 25, e13986.	0.5	6

#	ARTICLE	IF	CITATIONS
369	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. <i>PLoS ONE</i> , 2021, 16, e0248007.	1.1	32
370	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
372	Preliminary optimisation of a simplified sample preparation method to permit direct detection of SARS-CoV-2 within saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP). <i>Journal of Virological Methods</i> , 2021, 289, 114048.	1.0	31
373	COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200982.	1.5	31
374	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. <i>Viruses</i> , 2021, 13, 418.	1.5	51
375	COVID-19 in early 2021: current status and looking forward. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 114.	7.1	191
376	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2. <i>Npj Vaccines</i> , 2021, 6, 37.	2.9	14
378	Editor's introduction to this issue (G&I 19:1, 2021). <i>Genomics and Informatics</i> , 2021, 19, e1.	0.4	2
379	Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2021, 73, 1927-1939.	2.9	19
381	Wuhan to World: The COVID-19 Pandemic. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 596201.	1.8	115
382	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. <i>Diagnostics</i> , 2021, 11, 579.	1.3	114
383	Single-dose Oxford's AstraZeneca COVID-19 vaccine followed by a 12-week booster. <i>Lancet</i> , The, 2021, 397, 854-855.	6.3	55
384	Current progress and challenges in the design and development of a successful COVID-19 vaccine. <i>Fundamental Research</i> , 2021, 1, 139-150.	1.6	19
385	Recombinant protein vaccines, a proven approach against coronavirus pandemics. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 71-82.	6.6	157
386	Correlates of Vaccine-Induced Protection against SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 238.	2.1	49
387	SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. <i>Genome Medicine</i> , 2021, 13, 43.	3.6	44
388	Potential interactions between COVID-19 vaccines and antiepileptic drugs. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 86, 80-81.	0.9	17
389	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541

#	ARTICLE	IF	CITATIONS
390	Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. <i>Infectious Diseases</i> , 2021, 53, 498-512.	1.4	12
391	Does Macrophage Migration Inhibitory Factor predict the prognosis of COVID-19 disease?. <i>Journal of Infection in Developing Countries</i> , 2021, 15, 398-403.	0.5	8
392	The global race to develop a COVID-19 vaccine. <i>Practice Nursing</i> , 2021, 32, S7-S9.	0.1	0
394	Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19. , 0, , .		0
395	Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. <i>Current Clinical Microbiology Reports</i> , 2021, 8, 178-185.	1.8	46
396	Frontrunners in the race to develop a SARS-CoV-2 vaccine. <i>Canadian Journal of Microbiology</i> , 2021, 67, 189-212.	0.8	11
400	The effect of age on the incidence of COVID-19 complications: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021, 10, 80.	2.5	30
402	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262
403	Novel approaches for vaccine development. <i>Cell</i> , 2021, 184, 1589-1603.	13.5	145
404	A Review of the Animal and Human Trials of the Ad5-nCoV Vaccine Candidate. <i>Journal of Student Research</i> , 2021, 10, .	0.0	2
405	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2021, 14, 331-346.	1.9	12
406	Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. <i>Journal of College of Medical Sciences-Nepal</i> , 2021, 11, 959-982.	0.2	17
407	Vaccination for COVID-19: Is it important and what should you know about it?. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	6
408	SARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort. <i>Clinical Medicine</i> , 2021, 21, e243.2-e243.	0.8	2
409	Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. <i>Vaccines</i> , 2021, 9, 296.	2.1	6
410	SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	213
411	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
412	The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. <i>Viruses</i> , 2021, 13, 425.	1.5	27

#	ARTICLE	IF	CITATIONS
413	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 113-141.	6.6	71
414	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
415	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. <i>Bioscience Reports</i> , 2021, 41, .	1.1	16
417	Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro. <i>Frontiers in Immunology</i> , 2021, 12, 613045.	2.2	14
418	COVID-19: Insights into Potential Vaccines. <i>Microorganisms</i> , 2021, 9, 605.	1.6	31
420	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <i>Globalization and Health</i> , 2021, 17, 24.	2.4	40
421	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. <i>Science Advances</i> , 2021, 7, .	4.7	100
424	A risk assessment strategy to re-introduce elective neurosurgery patients during COVID-19. <i>British Journal of Neurosurgery</i> , 2024, 38, 476-480.	0.4	1
426	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. <i>Nature Protocols</i> , 2021, 16, 3114-3140.	5.5	195
428	Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. <i>Pharmaceutics</i> , 2021, 13, 501.	2.0	15
429	The COVID-19 Vaccines: Recent Development, Challenges and Prospects. <i>Vaccines</i> , 2021, 9, 349.	2.1	60
431	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. <i>Pharmaceutics</i> , 2021, 14, 406.	1.7	101
432	Immunogenicity of the Ad26.COVS.2 Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
433	How to Understand Herd Immunity in the Context of COVID-19. <i>Viral Immunology</i> , 2021, 34, 174-181.	0.6	17
434	Current Advances in Novel SARS-CoV-2 Disease (COVID-19) Treatment and Intervention Strategies. <i>Coronaviruses</i> , 2021, 2, 353-358.	0.2	2
435	TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	5
436	Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development. <i>Pharmaceutics</i> , 2021, 14, 331.	1.7	20
437	The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response. <i>Vaccine</i> , 2021, 39, 2500-2503.	1.7	2

#	ARTICLE	IF	CITATIONS
438	Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational Study. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 123-129.	0.1	1
439	A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. <i>Virus Research</i> , 2021, 295, 198305.	1.1	14
440	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. <i>Vaccines</i> , 2021, 9, 433.	2.1	85
441	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602.	5.3	118
442	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
443	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
444	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
445	The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World. <i>Clinical Therapeutics</i> , 2021, 43, 702-710.	1.1	7
446	COVID-19 immunity and vaccines: what a pharmacist needs to know. <i>Asian Biomedicine</i> , 2021, 15, 51-67.	0.2	0
447	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. <i>Chinese Medical Journal</i> , 2021, 134, 1289-1298.	0.9	49
448	Paediatric research in the times of COVID-19. <i>Pediatric Research</i> , 2021, 90, 267-271.	1.1	8
449	COVID-19 Pandemic Is Associated with an Adverse Impact on Burnout and Mood Disorder in Healthcare Professionals. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3654.	1.2	16
450	Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. <i>Npj Vaccines</i> , 2021, 6, 53.	2.9	23
451	SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. <i>Microorganisms</i> , 2021, 9, 793.	1.6	20
453	Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. <i>Vaccines</i> , 2021, 9, 395.	2.1	32
454	Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. <i>AAPS PharmSciTech</i> , 2021, 22, 126.	1.5	41
455	Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach. <i>Viruses</i> , 2021, 13, 787.	1.5	13
456	Animal Models of COVID-19 II. <i>Comparative Immunology</i> . <i>ILAR Journal</i> , 2021, 62, 17-34.	1.8	20



#	ARTICLE	IF	CITATIONS
457	Vaccines Developed against COVID-19: a narrative review. Revista Da Associação Médica Brasileira, 2021, 67, 625-631.	0.3	0
459	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. Science Progress, 2021, 104, 003685042110169.	1.0	15
460	Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report. Vaccine, 2021, 39, 2479-2488.	1.7	4
461	Nanostrategies to Develop Current Antiviral Vaccines. ACS Applied Bio Materials, 2021, 4, 3880-3890.	2.3	3
462	Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. IScience, 2021, 24, 102298.	1.9	70
463	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight, 2021, 6, .	2.3	52
464	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Frontiers in Immunology, 2021, 12, 669339.	2.2	81
465	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. Cell Reports Medicine, 2021, 2, 100252.	3.3	33
466	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	1.0	16
467	Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1453-1462.	1.4	59
470	Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. Npj Vaccines, 2021, 6, 61.	2.9	66
471	SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight, 2021, 6, .	2.3	72
472	Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses. PLoS Neglected Tropical Diseases, 2021, 15, e0009308.	1.3	13
473	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. Journal of Biomaterials Science, Polymer Edition, 2021, 32, 1219-1249.	1.9	19
474	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. Journal of Virology, 2021, 95, .	1.5	7
475	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. Infectious Diseases & Immunity, 2021, 1, 43-51.	0.2	4
476	Current COVID-19 treatments: Rapid review of the literature. Journal of Global Health, 2021, 11, 10003.	1.2	26
477	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. Frontiers in Cellular and Infection Microbiology, 2021, 11, 639108.	1.8	13

#	ARTICLE	IF	CITATIONS
478	Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111272.	2.5	84
479	SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2356-2366.	1.4	64
480	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
482	COVID-19: Challenges, Preventive Measures and Remediation. <i>Oriental Journal of Chemistry</i> , 2021, 37, 285-294.	0.1	0
483	To get or not to get: Examining the intentions of Philippine teachers to vaccinate against COVID-19. <i>Journal of Human Behavior in the Social Environment</i> , 2022, 32, 325-335.	1.1	13
484	The importance of genomic analysis in cracking the coronavirus pandemic. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 547-562.	1.5	14
485	COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review. <i>Current Pharmaceutical Design</i> , 2021, 27, 1170-1184.	0.9	13
486	Microarray patches enable the development of skin-targeted vaccines against COVID-19. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 164-186.	6.6	45
487	Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes. <i>Public Health</i> , 2021, 193, 57-60.	1.4	10
488	Antibody Responses in COVID-19: A Review. <i>Frontiers in Immunology</i> , 2021, 12, 633184.	2.2	105
489	Coronavirus Disease 2019: An Overview of the Complications and Management. , 0, , 1-28.		1
491	Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): Epidemiology and Vaccinology in Nigeria. <i>International Journal of Travel Medicine and Global Health</i> , 2021, 9, 60-69.	0.1	2
492	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11
494	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 636.	1.2	2
495	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial. <i>Vaccine</i> , 2021, 39, 2746-2754.	1.7	43
497	Immune response induced by oral administration with a <i>Saccharomyces cerevisiae</i> -based SARS-CoV-2 vaccine in mice. <i>Microbial Cell Factories</i> , 2021, 20, 95.	1.9	23
498	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 1002-1015.	3.0	22
499	Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein. <i>Nature Communications</i> , 2021, 12, 2790.	5.8	26

#	ARTICLE	IF	CITATIONS
500	Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. <i>Lancet, The</i> , 2021, 397, 2043-2046.	6.3	231
501	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. <i>Npj Vaccines</i> , 2021, 6, 67.	2.9	47
505	Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. <i>Vaccine</i> , 2021, 39, 2995-3006.	1.7	71
506	Targets and strategies for vaccine development against SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111254.	2.5	58
507	Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. <i>Neurología (English Edition)</i> , 2021, 36, 451-461.	0.2	10
508	Relation between COVID-19 vaccination and myocardial infarction – Casual or coincidental?. <i>IHJ Cardiovascular Case Reports (CVCR)</i> , 2021, 5, 71-74.	0.0	11
509	Efforts to deploy COVID-19 vaccine in the WHO Eastern Mediterranean Region within the first 100 days of 2021. <i>Eastern Mediterranean Health Journal</i> , 2021, 27, 433-437.	0.3	6
510	Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. <i>Vaccines</i> , 2021, 9, 556.	2.1	140
511	A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. <i>Scientific Reports</i> , 2021, 11, 10617.	1.6	28
512	COVID-19 vaccines: progress and understanding on quality control and evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 199.	7.1	21
513	The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 484-495.	0.7	68
514	A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. <i>Nature Communications</i> , 2021, 12, 2623.	5.8	64
515	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. <i>BMJ, The</i> , 2021, 373, n1088.	3.0	881
516	SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development. <i>International Journal of Biological Macromolecules</i> , 2021, 179, 45-60.	3.6	14
517	Bioreactor production of rVSVΔG-based vectors in Vero cell suspension cultures. <i>Biotechnology and Bioengineering</i> , 2021, 118, 2649-2659.	1.7	15
518	Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. <i>Expert Review of Vaccines</i> , 2021, 20, 891-898.	2.0	67
519	Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. <i>Vaccines</i> , 2021, 9, 453.	2.1	11
520	Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. <i>European Journal of Pharmacology</i> , 2021, 898, 173977.	1.7	29

#	ARTICLE	IF	CITATIONS
521	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
522	Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. <i>PLoS Computational Biology</i> , 2021, 17, e1008849.	1.5	142
523	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. <i>International Reviews of Immunology</i> , 2021, , 1-16.	1.5	6
524	Advances of nanomaterialsâ€based strategies for fighting against COVIDâ€19. <i>View</i> , 2021, 2, 20200180.	2.7	16
525	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
526	Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1146-1153.	2.0	45
527	Delayed production of neutralizing antibodies correlates with fatal COVID-19. <i>Nature Medicine</i> , 2021, 27, 1178-1186.	15.2	183
528	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 637-646.	4.6	326
530	Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628585.	1.6	31
531	COVID-19 Vaccines Based on Adenovirus Vectors. <i>Trends in Biochemical Sciences</i> , 2021, 46, 429-430.	3.7	24
532	Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and inÂvitro validation of protease activity inhibition using an enzymatic inhibition assay. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107851.	1.3	29
533	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. <i>Biomedicines</i> , 2021, 9, 611.	1.4	10
534	Therapeutic Agents Against COVID-19 with Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1608-1617.	0.9	4
535	Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality. <i>Frontiers in Immunology</i> , 2021, 12, 659339.	2.2	33
536	Management of COVID-19: current status and future prospects. <i>Microbes and Infection</i> , 2021, 23, 104832.	1.0	18
537	Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine. <i>Emerging Microbes and Infections</i> , 2021, 10, 1112-1115.	3.0	24
538	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. <i>Vaccines</i> , 2021, 9, 520.	2.1	28
539	The dawn of mRNA vaccines: The COVID-19 case. <i>Journal of Controlled Release</i> , 2021, 333, 511-520.	4.8	276

#	ARTICLE	IF	CITATIONS
540	Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	12
541	Cutaneous adverse effects of the available COVID-19 vaccines. <i>Clinics in Dermatology</i> , 2021, 39, 523-531.	0.8	69
542	Tweet Topics and Sentiments Relating to COVID-19 Vaccination Among Australian Twitter Users: Machine Learning Analysis. <i>Journal of Medical Internet Research</i> , 2021, 23, e26953.	2.1	142
543	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
544	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
545	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	1.8	9
546	A importância da procalcitonina associado aos pacientes em tratamento de covid-19. <i>Research, Society and Development</i> , 2021, 10, e1210614872.	0.0	0
548	Dynamic causal modelling of immune heterogeneity. <i>Scientific Reports</i> , 2021, 11, 11400.	1.6	3
549	The need for ethical and pragmatic strategies for sample and data collection during public health emergencies – minimizing missed opportunities. <i>European Heart Journal</i> , 2021, 42, 3114-3116.	1.0	0
551	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
552	COVID-19 vaccine decisions: considering the choices and opportunities. <i>Microbes and Infection</i> , 2021, 23, 104811.	1.0	17
553	Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys. <i>Bioconjugate Chemistry</i> , 2021, 32, 1034-1046.	1.8	23
554	The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19. <i>Vaccines</i> , 2021, 9, 502.	2.1	52
555	Durability of the humoral immune response in recovered COVID-19 patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 2802-2806.	1.8	11
556	An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1813-1818.	1.9	84
557	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Vaccines</i> , 2021, 9, 467.	2.1	228
558	Interim Results of a Phase 1a Trial of Ad26.COV2.S Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 1824-1835.	13.9	962
559	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 1205-1211.	15.2	3,133

#	ARTICLE	IF	CITATIONS
560	Predictors of Intention to Vaccinate against COVID-19 in the General Public in Hong Kong: Findings from a Population-Based, Cross-Sectional Survey. <i>Vaccines</i> , 2021, 9, 696.	2.1	34
561	Genome-wide analysis of 10664 SARS-CoV-2 genomes to identify virus strains in 73 countries based on single nucleotide polymorphism. <i>Virus Research</i> , 2021, 298, 198401.	1.1	5
562	The Many Faces of Innate Immunity in SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 596.	2.1	10
564	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	5.8	44
565	Adenovirus and RNA-based COVID-19 vaccinesâ€™ perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey. <i>BMJ Open</i> , 2021, 11, e048586.	0.8	31
566	Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt. <i>Antibody Therapeutics</i> , 2021, 4, 135-143.	1.2	1
567	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
568	Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 577.	2.1	91
569	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. <i>Human Gene Therapy</i> , 2021, 32, 541-562.	1.4	9
570	Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom. <i>Clinical Trials</i> , 2021, 18, 615-621.	0.7	3
571	SARS-CoV-2 Vaccineâ€™ Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 384, 2254-2256.	13.9	412
572	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
573	COVID-19 and the Response of Transplant Centers: the Global Response with an Emphasis on the Kidney Recipient. <i>Current Transplantation Reports</i> , 2021, 8, 1-20.	0.9	4
575	COVID-19 vaccines: Frequently asked questions and updated answers. <i>Infectious Diseases Now</i> , 2021, 51, 319-333.	0.7	10
576	Quantitative SARS-CoV-2 anti-spike responses to Pfizerâ€™BioNTech and Oxfordâ€™AstraZeneca vaccines by previous infection status. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1516.e7-1516.e14.	2.8	100
577	COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
578	Key Considerations for the Development of Safe and Effective SARSâ€™CoVâ€™2 Subunit Vaccine: A Peptideâ€™Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
579	The contribution of veterinary public health to the management of the COVID-19 pandemic from a One Health perspective. <i>One Health</i> , 2021, 12, 100230.	1.5	21

#	ARTICLE	IF	CITATIONS
580	Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine. <i>Brain Hemorrhages</i> , 2021, 2, 165-167.	0.4	22
581	SARS-CoV-2 vaccines, where do we stand?. <i>Comptes Rendus - Biologies</i> , 2021, 344, 43-55.	0.1	3
582	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 701752.	2.2	17
583	COVID-19 Infection and Circulating Microparticles—Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4188-4215.	1.9	16
586	Thermotropic effects of PEGylated lipids on the stability of HPPH-encapsulated lipid nanoparticles (LNP). <i>Journal of Thermal Analysis and Calorimetry</i> , 2022, 147, 6337-6348.	2.0	11
589	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. <i>PLoS ONE</i> , 2021, 16, e0253487.	1.1	76
590	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). <i>Sovremennyye Tehnologii V Medicine</i> , 2021, 13, 81.	0.4	4
591	COVID-19 vaccine: Potential candidates, achievements, and challenges. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 15, 102-109.	0.1	0
592	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
593	Updates on the coronavirus disease 2019 vaccine and consideration in children. <i>Clinical and Experimental Pediatrics</i> , 2021, 64, 328-338.	0.9	8
594	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120686.	2.6	83
595	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. <i>Medicine in Drug Discovery</i> , 2021, 10, 100085.	2.3	19
596	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. <i>Frontiers in Pharmacology</i> , 2021, 12, 659577.	1.6	31
598	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <i>Public Health Reviews</i> , 2021, 42, 1604061.	1.3	6
599	Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study. <i>EBioMedicine</i> , 2021, 68, 103414.	2.7	17
600	Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine. <i>Journal of Clinical Medicine</i> , 2021, 10, 2844.	1.0	12
603	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3575-3583.	2.0	41
605	COVID-19 vaccine development from the perspective of cancer patients. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3281-3287.	1.4	4

#	ARTICLE	IF	CITATIONS
606	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
608	Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate. <i>Journal of Virology</i> , 2021, 95, e0223220.	1.5	25
609	Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation. <i>Nanomedicine</i> , 2021, 16, 1219-1235.	1.7	32
611	The Effect of COVID-19 Vaccinations in 47 European Countries. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 134-140.	0.1	1
613	A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. <i>Molecular Therapy</i> , 2021, 29, 1970-1983.	3.7	111
614	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	2.2	23
615	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477.	2.6	58
616	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	64
617	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 803-812.	4.6	415
618	SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches. <i>Applied Nanoscience (Switzerland)</i> , 2023, 13, 65-93.	1.6	8
619	A protein interactions map of multiple organ systems associated with COVID-19 disease. <i>Genomics and Informatics</i> , 2021, 19, e14.	0.4	2
620	COVID-19 Vaccines in Patients With Chronic Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 720-726.	0.4	17
621	An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1652-1666.	0.6	38
622	A rational strategy to support approved COVID-19 vaccines prioritization. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3474-3477.	1.4	4
623	The Safety of COVID-19 Vaccinationsâ€”We Should Rethink the Policy. <i>Vaccines</i> , 2021, 9, 693.	2.1	23
624	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
626	Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3355.	1.0	12
627	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. <i>Journal of Virology</i> , 2021, 95, e0020321.	1.5	35



#	ARTICLE	IF	CITATIONS
628	COVISHIELD (AZD1222) Vaccine effectiveness among healthcare and frontline Workers of Indian Armed Forces: Interim results of VIN-WIN cohort study. Medical Journal Armed Forces India, 2021, 77, S264-S270.	0.3	45
629	Inflating the role of stromal cells in CD8+ T cell memory. Nature Immunology, 2021, 22, 942-944.	7.0	1
630	Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19. Current Pharmaceutical Design, 2022, 28, 948-968.	0.9	10
631	Genomic Surveillance and Phylodynamic Analyses Reveal the Emergence of Novel Mutations and Co-mutation Patterns Within SARS-CoV-2 Variants Prevalent in India. Frontiers in Microbiology, 2021, 12, 703933.	1.5	5
633	Impacto de la Covid-19 en las personas con discapacidades intelectuales y del desarrollo, sus familiares y los profesionales y organizaciones de apoyo. Siglo Cero, 2021, , 11-36.	0.2	3
634	Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. Euro-Mediterranean Journal for Environmental Integration, 2021, 6, 61.	0.6	0
636	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clinical Microbiology and Infection, 2021, 27, 1784-1789.	2.8	54
637	COVID-19 Vaccines: Fabrication Techniques and Current Status. Coronaviruses, 2021, 02, .	0.2	0
638	A contemporary insight into SARS-CoV-2 pathophysiology, retrieved threat of mutants and prospect of vaccine development. Minerva Biotechnology and Biomolecular Research, 2021, 33, .	0.3	7
639	3D Printing Technology for Fighting COVID-19 Pandemic. Lecture Notes in Bioengineering, 2022, , 81-109.	0.3	1
640	How to interpret and use COVID-19 serology and immunology tests. Clinical Microbiology and Infection, 2021, 27, 981-986.	2.8	94
641	Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against COVID-19 and the urgent need of a large immunization in healthcare workers. Therapie, 2021, , .	0.6	1
642	COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. Journal of Intensive Medicine, 2021, 1, 4-13.	0.8	9
643	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Frontiers in Immunology, 2021, 12, 701501.	2.2	157
644	Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. Nature Communications, 2021, 12, 4396.	5.8	24
645	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 2021, 19, 173.	2.3	156
646	Cutaneous thrombosis associated with skin necrosis following Oxfordâ€AstraZeneca COVIDâ€19 vaccination. Clinical and Experimental Dermatology, 2021, 46, 1610-1612.	0.6	17
649	COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Review of Vaccines, 2021, 20, 1013-1025.	2.0	56

#	ARTICLE	IF	CITATIONS
650	Early approval of COVID-19 vaccines: Pros and cons. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3288-3296.	1.4	14
651	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. <i>PLoS Pathogens</i> , 2021, 17, e1009761.	2.1	66
652	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 1331-1346.	1.9	7
653	Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults. <i>Biomedicines</i> , 2021, 9, 868.	1.4	5
655	Serological survey of antibodies against SARS-CoV-2 in dogs and cats, Thailand. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2140-2147.	1.3	27
656	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? – The Summarising Review. <i>International Journal of Public Health</i> , 2021, 66, 1603975.	1.0	3
657	Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review. <i>Journal of Infection and Public Health</i> , 2021, 14, 910-921.	1.9	14
658	Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. <i>Infectious Diseases of Poverty</i> , 2021, 10, 94.	1.5	109
659	Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?. <i>Vaccines</i> , 2021, 9, 761.	2.1	17
660	New perspective towards therapeutic regimen against SARS-CoV-2 infection. <i>Journal of Infection and Public Health</i> , 2021, 14, 852-862.	1.9	3
661	Recent developments and opportunities in fighting COVID-19. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
662	Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study. <i>Medical Journal Armed Forces India</i> , 2021, 77, S283-S288.	0.3	41
663	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. <i>Infection</i> , 2022, 50, 11-25.	2.3	50
664	Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March~June 2021, England. <i>Eurosurveillance</i> , 2021, 26, .	3.9	47
665	Human Coronaviruses: Counteracting the Damage by Storm. <i>Viruses</i> , 2021, 13, 1457.	1.5	5
666	Coronavirus disease 2019 vaccines: perspectives and update. <i>Medical Journal Armed Forces India</i> , 2021, 77, S245-S249.	0.3	1
668	Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions. <i>Viruses</i> , 2021, 13, 1300.	1.5	9
670	Improvement strategies of food supply chain through novel food processing technologies during COVID-19 pandemic. <i>Food Control</i> , 2021, 125, 108010.	2.8	67

#	ARTICLE	IF	CITATIONS
671	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	2.0	15
672	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. <i>Nature Medicine</i> , 2021, 27, 1744-1751.	15.2	148
673	Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 356, 577599.	1.1	62
674	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 950-961.	4.6	271
675	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
676	Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomains Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. <i>Covid</i> , 2021, 1, 105-114.	0.7	6
679	Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines. <i>Vaccines</i> , 2021, 9, 820.	2.1	18
680	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	5.8	31
681	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Î±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 719077.	2.2	9
682	Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. <i>Medical Journal Armed Forces India</i> , 2021, 77, S505-S507.	0.3	18
684	Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
685	Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8+ T cells. <i>Nature Immunology</i> , 2021, 22, 1042-1051.	7.0	30
686	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. <i>Molecular Biology</i> , 2021, 55, 538-547.	0.4	2
687	Prolonged humoral and cellular immunity in COVID-19-recovered patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4010-4015.	1.8	12
688	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
689	AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. <i>Lancet</i> , The, 2021, 398, 207-209.	6.3	112
690	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 398, 121-130.	6.3	316
691	Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. <i>Scientific Reports</i> , 2021, 11, 15295.	1.6	5

#	ARTICLE	IF	CITATIONS
692	Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19). <i>Blood</i> , 2021, 138, 996-999.	0.6	15
694	High-precision and cost-efficient sequencing for real-time COVID-19 surveillance. <i>Scientific Reports</i> , 2021, 11, 13669.	1.6	15
695	Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 53.	1.3	1
696	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	1.5	33
697	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <i>ACS Infectious Diseases</i> , 2021, 7, 2546-2564.	1.8	34
698	Shedding UVC light on Covid-19 to protect dentistry staff and patients. <i>Laser Physics Letters</i> , 2021, 18, 085602.	0.6	2
700	Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance. <i>IScience</i> , 2021, 24, 102780.	1.9	4
701	Adverse Events Following COVISHIELD Vaccination Among Adult Population in Bangladesh. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 2207-2213.	0.3	5
702	Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?. <i>Pharmaceuticals</i> , 2021, 14, 730.	1.7	8
703	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
704	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 328-333.	1.0	7
705	COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. <i>Nature Medicine</i> , 2021, 27, 1385-1394.	15.2	704
706	COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?. <i>Journal of Ophthalmic and Vision Research</i> , 2021, 16, 490-501.	0.7	62
707	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
709	Posicionamiento de la Sociedad Española de Nefrología ante la vacunación frente al SARS-CoV-2. <i>Nefrología</i> , 2021, 41, 412-416.	0.2	4
710	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. <i>Cell Research</i> , 2021, 31, 1011-1023.	5.7	48
711	<i>Nigella Sativa</i> : An Immunity Booster as Pandemic Treatment Solution Against SARS-CoV-2. <i>Coronaviruses</i> , 2021, 2, .	0.2	2
714	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88

#	ARTICLE	IF	CITATIONS
715	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. <i>Pain and Therapy</i> , 2021, 10, 1309-1330.	1.5	28
716	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
718	COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. <i>Cancers</i> , 2021, 13, 3573.	1.7	39
719	Oxford's AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign. <i>Public Health</i> , 2021, 196, 135-137.	1.4	10
720	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
721	With Great Hopes Come Great Expectations: Access and Adoption Issues Associated With COVID-19 Vaccines. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e26111.	1.2	21
722	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
723	Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Vaccines</i> , 2021, 9, 939.	2.1	25
724	COVID-19 and the flu: data simulations and computational modelling to guide public health strategies. <i>Family Practice</i> , 2021, 38, i16-i22.	0.8	3
725	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. <i>Npj Vaccines</i> , 2021, 6, 97.	2.9	175
726	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. <i>Infection</i> , 2021, 49, 855-876.	2.3	61
727	A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. <i>EClinicalMedicine</i> , 2021, 38, 101038.	3.2	50
728	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 910.	2.1	50
729	Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. <i>Molecular Therapy</i> , 2021, 29, 2412-2423.	3.7	41
730	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. <i>EClinicalMedicine</i> , 2021, 38, 100989.	3.2	56
731	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1107-1119.	4.6	345
732	Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo. <i>PLoS ONE</i> , 2021, 16, e0256401.	1.1	57
733	Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. <i>Pathogens</i> , 2021, 10, 1051.	1.2	18

#	ARTICLE	IF	CITATIONS
734	Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. <i>Expert Review of Vaccines</i> , 2022, 21, 957-974.	2.0	51
735	COVID 19 and vaccine safety. <i>Journal of Education, Health and Sport</i> , 2021, 11, 313-321.	0.0	0
737	Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021, 184, 4401-4413.e10.	13.5	65
738	The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 7205-7214.	1.9	9
740	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
741	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1322-1329.	0.5	188
742	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2021, 93, 6737-6749.	2.5	13
743	Sociodemographic and Psychological Predictors of Intention to Receive a COVID-19 Vaccine in Elderly Peruvians. <i>Trends in Psychology</i> , 2022, 30, 206-223.	0.7	15
744	Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive Immunity. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	1.0	10
745	Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2. <i>Drugs in R and D</i> , 2021, 21, 371-374.	1.1	12
746	Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19. <i>Vaccines</i> , 2021, 9, 928.	2.1	12
747	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
748	SARS-CoV-2 vaccines "the biggest medical research project of the 21st century. <i>Current Opinion in Virology</i> , 2021, 49, 52-57.	2.6	12
751	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021, 8, e474-e485.	2.1	190
752	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
753	Analysis of COVID-19 vaccines: Types, thoughts, and application. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23937.	0.9	61
755	Promising Technologies in the Field of Helminth Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 711650.	2.2	24
756	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. <i>Viruses</i> , 2021, 13, 1645.	1.5	8

#	ARTICLE	IF	CITATIONS
757	A potential bat adenovirus-based oncolytic virus targeting canine cancers. <i>Scientific Reports</i> , 2021, 11, 16706.	1.6	4
758	Systemic IL-15, IFN- $\beta$ , and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. <i>Cell Reports</i> , 2021, 36, 109504.	2.9	137
760	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
761	Expediting in vitro characterization of mRNA-based gene therapies via high-content fluorescent imaging. <i>Analytical Biochemistry</i> , 2021, 627, 114259.	1.1	2
762	Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. <i>Haematologica</i> , 2021, 106, 3034-3045.	1.7	24
763	Amplicon and Metagenomic Analysis of Middle East Respiratory Syndrome (MERS) Coronavirus and the Microbiome in Patients with Severe MERS. <i>MSphere</i> , 2021, 6, e0021921.	1.3	12
764	Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 376-382.	0.3	30
765	COVID-19 Vaccination Associated With Reduced Postoperative SARS-CoV-2 Infection and Morbidity. <i>Annals of Surgery</i> , 2022, 275, 31-36.	2.1	31
766	COVID-19 Tanımlı Testleri, Tedavisindeki Ayrıntılar ve İzlenimler; Güncel Durum. <i>Uludağ Üniversitesi Tıp Fakültesi Dergisi</i> , 2021, 47, 295-308.	0.2	1
767	Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review. <i>The Open Covid Journal</i> , 2021, 1, 65-76.	0.4	0
768	Cardiovascular Complication following Covishield Vaccination in Nepal: A Case Report. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 805-807.	0.1	3
769	The dynamics of quantitative SARS-CoV-2 antispikes IgG response to BNT162b2 vaccination. <i>Journal of Medical Virology</i> , 2021, 93, 6813-6817.	2.5	8
770	Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. <i>Vaccines</i> , 2021, 9, 950.	2.1	18
771	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	2.1	15
772	An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines. <i>Journal of Clinical Medicine</i> , 2021, 10, 3817.	1.0	16
773	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1255-1265.	5.2	279
774	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	251
777	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. <i>International Immunopharmacology</i> , 2021, 97, 107679.	1.7	9

#	ARTICLE	IF	CITATIONS
778	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. <i>International Immunopharmacology</i> , 2021, 97, 107622.	1.7	14
779	The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review. <i>Vaccines</i> , 2021, 9, 885.	2.1	57
780	SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications. <i>ACS Sensors</i> , 2021, 6, 2815-2837.	4.0	24
781	Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0110521.	1.8	21
782	History, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). <i>Coronaviruses</i> , 2021, 02, .	0.2	1
784	AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories. <i>Clinical Chemistry</i> , 2021, 67, 1188-1200.	1.5	20
785	Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/III clinical study by intradermal route in healthy subjects in India. <i>EClinicalMedicine</i> , 2021, 38, 101020.	3.2	121
786	Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1110-1123.	1.9	26
788	A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination. <i>Acta Clinica Belgica</i> , 2022, 77, 772-777.	0.5	11
789	Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020. <i>Biosafety and Health</i> , 2021, 3, 264-275.	1.2	11
790	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	23
791	Herpes zoster after COVID-19 vaccination—Can the vaccine reactivate latent zoster virus?. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 3376-3377.	0.8	17
792	A Self-Biomineralized Novel Adenovirus Vected COVID-19 Vaccine for Boosting Immunization of Mice. <i>Virologica Sinica</i> , 2021, 36, 1113-1123.	1.2	11
793	Antibody response after first and second-dose of ChAdOx1-nCoV (Covishield™) and BBV-152 (Covaxin™) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. <i>Vaccine</i> , 2021, 39, 6492-6509.	1.7	95
794	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
795	Adverse events and preventive measures related to COVID-19 vaccines. <i>Clinical and Experimental Emergency Medicine</i> , 2021, 8, 153-159.	0.5	1
796	Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation. <i>Nature Communications</i> , 2021, 12, 5333.	5.8	64
797	Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report. <i>Vaccines</i> , 2021, 9, 1078.	2.1	34



#	ARTICLE	IF	CITATIONS
798	Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 1049-1051.	13.9	137
799	Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 742914.	2.2	52
800	Learning from the global response to COVID-19 to accelerate innovation in mental health trials. <i>World Psychiatry</i> , 2021, 20, 358-359.	4.8	9
801	Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT). <i>BMJ Case Reports</i> , 2021, 14, e245218.	0.2	11
802	A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. <i>Journal of Neuroimmunology</i> , 2021, 358, 577606.	1.1	73
803	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
805	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	2.1	124
806	Innovative Solutions to the Clinical Challenges of COVID-19. <i>EAI/Springer Innovations in Communication and Computing</i> , 2022, , 337-351.	0.9	0
807	Thromboinflammatory findings and clinical predictors of mortality in vaccine-induced immune thrombotic thrombocytopenia. <i>European Heart Journal</i> , 2021, 42, 4073-4076.	1.0	1
808	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
809	Neutralization antibody titers against SARS-CoV-2 in an infant born to a mother with COVID-19. <i>Pediatrics and Neonatology</i> , 2021, 62, 661-663.	0.3	3
811	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847.	5.8	40
812	Potential Effects of Coronaviruses on the Liver: An Update. <i>Frontiers in Medicine</i> , 2021, 8, 651658.	1.2	38
813	Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice. <i>Reproductive Toxicology</i> , 2021, 104, 134-142.	1.3	19
814	Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies. <i>British Journal of Haematology</i> , 2021, 195, 706-709.	1.2	16
815	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 2348-2360.	13.9	458
816	Immune Responses against SARS-CoV-2—Questions and Experiences. <i>Biomedicines</i> , 2021, 9, 1342.	1.4	10
817	A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. <i>BMJ</i> , 2021, 374, n2061.	3.0	1,567

#	ARTICLE	IF	CITATIONS
818	Role of different types of nanomaterials against diagnosis, prevention and therapy of COVID-19. <i>Sustainable Cities and Society</i> , 2021, 72, 103046.	5.1	25
819	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
821	Optimising SARS-CoV-2 vaccination schedules. <i>Lancet, The</i> , 2021, 398, 819-821.	6.3	3
822	The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 340.	7.1	48
823	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. <i>Medicina (Lithuania)</i> , 2021, 57, 997.	0.8	9
824	Comparison of hospitalizations and deaths from COVID-19 2021 versus 2020 in Italy: surprises and implications. <i>F1000Research</i> , 2021, 10, 964.	0.8	2
825	Review of COVID-19 viral vector-based vaccines and COVID-19 variants. <i>Infezioni in Medicina</i> , 2021, 29, 328-338.	0.7	35
826	Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh. <i>Expert Review of Vaccines</i> , 2021, 20, 1651-1660.	2.0	13
827	Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. <i>Frontiers in Immunology</i> , 2021, 12, 652252.	2.2	13
828	Evaluation of adverse effects with COVID-19 vaccination in Pakistan. <i>Pakistan Journal of Medical Sciences</i> , 2021, 37, 1959-1964.	0.3	15
829	Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2022, 33, 110-136.	1.9	4
830	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
831	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. <i>Journal of Immunological Methods</i> , 2021, 499, 113160.	0.6	12
832	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
834	Healthcare Staff Perceptions Following Inoculation with the BNT162b2 mRNA COVID-19 Vaccine at University Hospitals Coventry & Warwickshire NHS Trust. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9378.	1.2	2
835	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	1.5	12
836	Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 166-185.	0.6	5
838	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. <i>PLoS ONE</i> , 2021, 16, e0257191.	1.1	19

#	ARTICLE	IF	CITATIONS
839	Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 1047.	2.1	23
840	Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection. <i>Vaccines</i> , 2021, 9, 1028.	2.1	11
841	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12
842	National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. <i>Public Health</i> , 2021, 198, 102-105.	1.4	4
843	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
844	Safety and Immunogenicity of a Recombinant Adenovirus Type-5â€“Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged â‰¥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e783-e791.	2.9	71
845	Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea. <i>Vaccines</i> , 2021, 9, 1096.	2.1	15
846	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
847	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848.	2.2	7
848	Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 738049.	1.2	7
849	Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines. <i>Nefrologia</i> , 2021, 41, 412-416.	0.2	6
850	A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18â€“59 years: An interim analysis in Indonesia. <i>Vaccine</i> , 2021, 39, 6520-6528.	1.7	97
851	Development of 3D+G printing for the design of customizable flow reactors. <i>Chemical Engineering Journal</i> , 2022, 430, 132670.	6.6	15
854	Adverse Events Following AstraZeneca COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study among Healthcare and Non-healthcare Workers. <i>Intervirology</i> , 2021, . .	1.2	16
856	Safety and immunogenicity of a QazCovid-inÂ® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. <i>EClinicalMedicine</i> , 2021, 39, 101078.	3.2	37
857	Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis. <i>BMJ Case Reports</i> , 2021, 14, e245092.	0.2	12
858	Thrombosis formation after COVID-19 vaccination Immunological Aspects: Review article. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 1073-1078.	1.8	8
861	An immunologist's perspective on anti-COVID-19 vaccines. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, Publish Ahead of Print, 545-552.	1.1	4

#	ARTICLE	IF	CITATIONS
862	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
863	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
864	Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 880.e1-880.e4.	0.6	27
865	Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association?. <i>Journal of Neuroimmunology</i> , 2021, 359, 577686.	1.1	27
866	SARS-CoV spike proteins can compete for electrolytes in physiological fluids according to structure-based quantum-chemical calculations. <i>Computational and Theoretical Chemistry</i> , 2021, 1204, 113392.	1.1	1
867	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. <i>Clinical Immunology</i> , 2021, 231, 108804.	1.4	5
868	Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1126-1130.	1.4	7
869	Herpes zoster after COVID vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 111, 169-171.	1.5	48
870	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1383-1394.	4.6	82
871	Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. <i>Journal of Controlled Release</i> , 2021, 338, 813-836.	4.8	30
873	Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort. <i>Science Bulletin</i> , 2021, 66, 2312-2319.	4.3	26
874	Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue. <i>International Immunopharmacology</i> , 2021, 100, 108150.	1.7	12
875	SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112176.	2.5	51
876	MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103225.	0.9	16
877	The impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey. <i>Epilepsy and Behavior</i> , 2021, 124, 108258.	0.9	15
878	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. <i>International Immunopharmacology</i> , 2021, 100, 108108.	1.7	7
879	Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence?. <i>Clinical Imaging</i> , 2021, 80, 348-352.	0.8	32
880	A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. <i>The Lancet Regional Health Americas</i> , 2021, 4, 100079.	1.5	27

#	ARTICLE	IF	CITATIONS
881	How does biological sex affect the physiological response to nanomaterials?. Nano Today, 2021, 41, 101292.	6.2	6
882	Evaluation of Covid-19 Awareness and Understanding Amongst Pharmacy Students at Gayatri College of Pharmacy Sambalpur, Odisha. International Journal of Current Research and Review (discontinued), 2021, 13, 26-31.	0.1	0
883	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. SSRN Electronic Journal, 0, , .	0.4	0
885	COVID-19 pandemic and the answer of science: a year in review. Anais Da Academia Brasileira De Ciencias, 2021, 93, e20210543.	0.3	4
886	Principles and Challenges in anti-COVID-19 Vaccine Development. International Archives of Allergy and Immunology, 2021, 182, 339-349.	0.9	38
887	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerging Microbes and Infections, 2021, 10, 1574-1588.	3.0	18
888	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	1.2	18
889	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, .	1.2	14
890	As the Pandemic Progresses, How Does Willingness to Vaccinate against COVID-19 Evolve?. International Journal of Environmental Research and Public Health, 2021, 18, 797.	1.2	81
891	SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results. SSRN Electronic Journal, 0, , .	0.4	2
892	Vaccine Effectiveness Against Infection and Death Due to SARS-CoV-2, Following One and Two Doses of the BNT162b2 and ChAdOx-1 in Residents of Long-Term Care Facilities in England, Using a Time-Varying Proportional Hazards Model. SSRN Electronic Journal, 0, , .	0.4	4
893	A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: male versus female outcomes. Journal of Advanced Pharmacy Education and Research, 2021, 11, 51-56.	0.2	21
894	Current State of the First COVID-19 Vaccines. Vaccines, 2021, 9, 30.	2.1	64
896	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Molecular Pharmaceutics, 2021, 18, 754-771.	2.3	193
897	Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2. Informatics in Medicine Unlocked, 2021, 24, 100578.	1.9	41
898	Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. Cell Reports Medicine, 2021, 2, 100185.	3.3	41
899	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Network, 2021, 21, e4.	1.6	26
900	Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens. Frontiers in Immunology, 2020, 11, 601170.	2.2	33

#	ARTICLE	IF	CITATIONS
903	Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic. <i>Immune Network</i> , 2021, 21, e5.	1.6	21
904	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
905	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	1.2	60
906	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
907	Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. <i>Cell Reports Medicine</i> , 2021, 2, 100187.	3.3	26
908	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. <i>Pediatric Infection and Vaccine</i> , 2021, 28, 7.	0.1	7
909	Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. <i>Frontiers in Immunology</i> , 2020, 11, 607333.	2.2	21
910	Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e115.	1.1	111
911	Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. <i>Journal of Korean Medical Science</i> , 2021, 36, e107.	1.1	57
912	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <i>Science China Life Sciences</i> , 2020, 63, 1833-1849.	2.3	29
913	Coronavirus vaccines leap through safety trials “ but which will work is anybody’s guess. <i>Nature</i> , 2020, 583, 669-670.	13.7	7
914	China’s coronavirus vaccines are leaping ahead “ but face challenges as virus wanes. <i>Nature</i> , 2020, 584, 17-18.	13.7	3
915	Researchers highlight “questionable” data in Russian coronavirus vaccine trial results. <i>Nature</i> , 2020, 585, 493-493.	13.7	5
916	SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa555.	0.4	66
917	The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2020, 8, e3206.	0.3	9
918	Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 9-13.	0.6	2
919	COVID-19 vaccine development: a pediatric perspective. <i>Current Opinion in Pediatrics</i> , 2021, 33, 144-151.	1.0	76
978	Antibody response to SARS-CoV-2 infection in humans: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0244126.	1.1	269

#	ARTICLE	IF	CITATIONS
979	A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. PLoS ONE, 2020, 15, e0244418.	1.1	16
980	The Chemopreventive Potential of Diosmin and Hesperidin for COVID-19 and Its Comorbid Diseases. Indonesian Journal of Cancer Chemoprevention, 2020, 11, 154.	0.3	8
981	SCIENTISTâ€™S PURSUIT FOR CORONAVIRUS SARS-COV-2, WHICH CAUSES COVID-19: SCIENTIFIC STRATEGIES AGAINST PANDEMIC. Visnik Nacional Noi Akademii Nauk Ukraini, 2020, , 29-71.	0.0	6
982	COVID-19 vaccines - are we there yet?. Australian Prescriber, 2021, 44, 19-25.	0.5	15
984	Nature Of, Immune Reaction and Side Effects of COVID-19 Vaccines: Synthesis of Information from Ten Phase II Trials for Planning Vaccination Programmes. SSRN Electronic Journal, 0, , .	0.4	3
985	&lt;p&gt;Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study from Jordan&lt;p&gt;. Patient Preference and Adherence, 2020, Volume 14, 2451-2458.	0.8	31
986	Vaccines against Coronavirus Disease: Target Proteins, Immune Responses, and Status of Ongoing Clinical Trials. Journal of Pure and Applied Microbiology, 2020, 14, 2253-2263.	0.3	3
987	Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. Eurosurveillance, 2020, 25, .	3.9	28
988	Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 146-158.	0.2	8
989	Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 228-244.	0.2	1
990	Vaccines against Covid-19: the Comparative Estimates of Risks in Adenovirus Vectors. Epidemiologiya I Vaksinoprofilaktika, 2020, 19, 4-17.	0.2	8
991	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. International Journal of Molecular Sciences, 2020, 21, 9775.	1.8	40
992	SARS-CoV-2 Spike Protein and Lung Vascular Cells. Journal of Respiration, 2021, 1, 40-48.	0.4	6
993	Viral Vector Vaccines against Bluetongue Virus. Microorganisms, 2021, 9, 42.	1.6	14
994	Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses, 2021, 13, 54.	1.5	61
995	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. Vaccines, 2020, 8, 783.	2.1	13
996	Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian Journal of Medical Research, 2021, 153, 93.	0.4	28
997	COVID-19 research risks ignoring important host genes due to pre-established research patterns. ELife, 2020, 9, .	2.8	14

#	ARTICLE	IF	CITATIONS
999	Poor Antibody Responses to SARS-CoV-2 Infection or Vaccination Are Associated With High Re-Infection Rates in Haemodialysis and Renal Transplant Patients. SSRN Electronic Journal, 0, , .	0.4	0
1000	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
1001	COVID-19: What have we learned since the beginning of the epidemic until today?. <i>Srpski Medicinski Åasopis Lekarske Komore</i> , 2021, 2, 248-265.	0.1	0
1002	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
1003	Antibody Responses After Oxford Astrazeneca (Covishield) Vaccine Among Healthcare Workers in Dhaka Medical College, Dhaka, Bangladesh. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1004	Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. <i>Clinical and Translational Immunology</i> , 2021, 10, e1345.	1.7	14
1005	“First Do No Harm” No-Fault Compensation Program for COVID-19 Vaccines as Feasibility and Wisdom of a Policy Instrument to Mitigate Vaccine Hesitancy. <i>Vaccines</i> , 2021, 9, 1116.	2.1	14
1006	COVID-19 Vaccines: Adenoviral Vectors. <i>Annual Review of Medicine</i> , 2022, 73, 41-54.	5.0	46
1007	Effectiveness of COVID-19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23
1008	BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. <i>Frontiers in Medicine</i> , 2021, 8, 760047.	1.2	84
1009	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. <i>Nano Research</i> , 2022, 15, 2196-2225.	5.8	8
1010	Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review. <i>Value in Health</i> , 2021, , .	0.1	7
1011	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11159.	1.2	11
1012	Innovations and development of Covid-19 vaccines: A patent review. <i>Journal of Infection and Public Health</i> , 2022, 15, 123-131.	1.9	27
1013	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
1014	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	4
1015	WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. <i>Lancet Microbe</i> , The, 2022, 3, e235-e240.	3.4	108
1016	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3



#	ARTICLE	IF	CITATIONS
1017	Tracking the progress in COVID-19 and vaccine safety research – a comprehensive bibliometric analysis of publications indexed in Scopus database. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3887-3897.	1.4	11
1018	Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. <i>Cell Discovery</i> , 2021, 7, 91.	3.1	12
1019	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
1021	Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 4237-4247.	1.1	17
1022	SARS-CoV-2 Fears Green: The Chlorophyll Catabolite Pheophorbide A Is a Potent Antiviral. <i>Pharmaceuticals</i> , 2021, 14, 1048.	1.7	8
1023	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
1024	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
1025	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. <i>International Journal of Infectious Diseases</i> , 2022, 114, 165-174.	1.5	18
1026	Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. <i>Science</i> , 2021, 374, 995-999.	6.0	230
1027	Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models. <i>Frontiers in Microbiology</i> , 2021, 12, 698999.	1.5	1
1028	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
1029	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
1030	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 714170.	2.2	145
1031	How COVID-19 has changed medical research funding. <i>Interface Focus</i> , 2021, 11, 20210025.	1.5	10
1032	Thrombosis in pre- and post-vaccination phase of COVID-19. <i>European Heart Journal Supplements</i> , 2021, 23, E184-E188.	0.0	5
1033	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
1034	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. <i>Nature Communications</i> , 2021, 12, 5839.	5.8	67
1035	Comparative characteristics of COVID-19 vaccines used for mass immunisation. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 158-166.	0.2	6

#	ARTICLE	IF	CITATIONS
1036	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1396-1406.	5.2	105
1038	Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates. <i>Clinical Infectious Diseases</i> , 2022, 75, e764-e773.	2.9	5
1040	Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1371-1383.	1.1	12
1041	Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine. <i>Vaccine</i> , 2021, 39, 6980-6983.	1.7	3
1044	Comparing Five SARS-CoV-2 Antibody Assay Results Before and After the First and Second ChAdOx1 nCoV-19 Vaccination Among Health Care Workers: A Prospective Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0178821.	1.8	9
1047	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18
1048	A case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	4
1049	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
1050	Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial. <i>Clinical and Translational Science</i> , 2021, , .	1.5	1
1051	Development of synthetic antigen vaccines for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3855-3870.	1.4	4
1052	Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient. <i>Vaccines</i> , 2021, 9, 1140.	2.1	3
1053	Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. <i>Annals of Neurosciences</i> , 2021, 28, 201-218.	0.9	7
1054	Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays. <i>Practical Laboratory Medicine</i> , 2021, 27, e00257.	0.6	1
1055	Symptomology following mRNA vaccination against SARS-CoV-2. <i>Preventive Medicine</i> , 2021, 153, 106860.	1.6	7
1056	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112282.	2.5	10
1057	Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report. <i>Thrombosis Research</i> , 2021, 208, 14-17.	0.8	4
1058	PopulaĂo, ambiente e a covid-19. <i>TemĂticas</i> , 2020, 28, 314-341.	0.1	0
1064	Vaccine development and technology for SARS-CoV-2: Current insight. <i>Journal of Medical Virology</i> , 2022, 94, 878-896.	2.5	8

#	ARTICLE	IF	CITATIONS
1065	Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen. <i>BMC Genomics</i> , 2021, 22, 777.	1.2	3
1067	Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4099-4101.	1.4	10
1068	Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. <i>European Journal of Neurology</i> , 2022, 29, 555-563.	1.7	85
1069	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
1071	Epidemic Prediction and Analysis of COVID-19: A Mathematical Modelling Study. <i>Studies in Systems, Decision and Control</i> , 2022, , 797-819.	0.8	0
1072	COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. <i>Breast</i> , 2021, 60, 214-222.	0.9	19
1073	Inovação, propriedade intelectual e acesso a medicamentos e vacinas: o debate internacional na pandemia da Covid-19. <i>Liinc Em Revista</i> , 2020, 16, e5338.	0.1	4
1076	SARS-CoV-2: desde sus aspectos genómicos y estructurales hasta su tratamiento. <i>Atención Familiar</i> , 0, 27, 3.	0.0	1
1077	SARS-CoV-2 Leading Vaccine Candidates: Progress and Development. <i>Life and Science</i> , 2020, 1, 7.	0.1	0
1078	Research on Drugs and Vaccines for COVID-19 Should Be Conducted and Published With Caution. <i>Journal of Epidemiology</i> , 2020, 30, 574-575.	1.1	0
1079	Modern vaccines and coronavirus infections. <i>Issledovaniĭ I Praktika V Medicine</i> , 2020, 7, 135-154.	0.1	2
1080	Vaccines and Treatment of Coronavirus Disease 2019. <i>Korean Journal of Medicine</i> , 2020, 95, 364-369.	0.1	1
1082	To get vaccinated or not? Social psychological factors associated with vaccination intent for COVID-19. <i>Journal of Pacific Rim Psychology</i> , 2021, 15, 183449092110517.	1.0	18
1083	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
1084	Rapid and inexpensive purification of adenovirus vectors using an optimised aqueous two-phase technology. <i>Journal of Virological Methods</i> , 2022, 299, 114305.	1.0	4
1085	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. <i>Immune Network</i> , 2021, 21, e32.	1.6	51
1086	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
1087	COVID-19 Global Mortality: Comparing Actual and Modelled Patterns in Space and Time Using an Infection Fatality Rate (IFR) Model. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1088	Prospects of vaccine against COVID-19. Indian Journal of Community Medicine, 2020, 45, 391.	0.2	2
1089	COVID-19 y cadena de suministro de alimentos : estatus y perspectivas. , 2020, , 43-55.		1
1090	Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective. SSRN Electronic Journal, 0, , .	0.4	1
1091	Vaccine and vaccination as a part of human life: In view of Covid-19. Biotechnology Journal, 2021, 17, 2100188.	1.8	9
1093	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). Clinics in Laboratory Medicine, 2022, 42, 111-128.	0.7	8
1094	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. Nature Communications, 2021, 12, 6370.	5.8	3
1095	Characterization of Recombinant Chimpanzee Adenovirus C68 Low and High-Density Particles: Impact on Determination of Viral Particle Titer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 753480.	2.0	5
1096	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Reports, 2021, 25, 101417.	0.4	15
1097	Adverse events of Oxford/AstraZeneca's COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. IJID Regions, 2021, 1, 124-129.	0.5	12
1098	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe, The, 2022, 3, e11-e20.	3.4	25
1099	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. EBioMedicine, 2021, 73, 103637.	2.7	19
1100	The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduction and Targeted Therapy, 2021, 6, 387.	7.1	42
1101	Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses. Npj Vaccines, 2021, 6, 135.	2.9	7
1102	A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Medica, 2021, 63, 324-331.	0.2	8
1103	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 2021, 374, eabl9551.	6.0	111
1105	Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Current Medical Science, 2021, 41, 1081-1086.	0.7	11
1106	First cases of SARS-CoV-2 infection in dogs and cats in Thailand. Transboundary and Emerging Diseases, 2022, 69, .	1.3	28
1107	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. Vaccines, 2021, 9, 1277.	2.1	1

#	ARTICLE	IF	CITATIONS
1108	An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults. <i>Lancet Regional Health - Europe</i> , The, 2021, 11, 100241.	3.0	50
1115	The narrow road to a COVID-19 vaccine. <i>Indian Journal of Pharmacology</i> , 2020, 52, 333-334.	0.4	1
1116	The COVID-19 Vaccine Saga: A Perspective. <i>Journal of Research in Pharmacy Practice</i> , 2020, 9, 218-219.	0.2	0
1117	Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2021, 12, 215-221.	0.4	2
1118	The Ethics of Selective Mandatory Vaccination for COVID-19. <i>Public Health Ethics</i> , 2022, 15, 74-86.	0.4	11
1119	Viral-vectored vaccines against SARS-CoV-2. , 2022, , 115-127.		1
1120	Side-effect expectations from COVID-19 vaccination: Findings from a nationally representative cross-sectional survey (CoVaccS "wave 2"). <i>Journal of Psychosomatic Research</i> , 2022, 152, 110679.	1.2	8
1121	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. <i>Transplant Immunology</i> , 2022, 70, 101495.	0.6	58
1122	Detection of Cytokine-Secreting Cells by Enzyme-Linked Immunospot (ELISpot). <i>Methods in Molecular Biology</i> , 2022, 2386, 61-79.	0.4	3
1123	A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display. <i>Microorganisms</i> , 2021, 9, 2414.	1.6	6
1124	PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. <i>JCI Insight</i> , 2021, 6, .	2.3	51
1125	Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19. <i>Vaccines</i> , 2021, 9, 1337.	2.1	28
1126	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
1127	Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 416-421.	0.5	19
1129	Beneficial Properties of Bromelain. <i>Nutrients</i> , 2021, 13, 4313.	1.7	33
1130	COVID-19 vaccines mix and match: The concept, the efficacy and the doubts. <i>Journal of Medical Virology</i> , 2022, 94, 1294-1299.	2.5	69
1132	Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. <i>Frontiers in Immunology</i> , 2021, 12, 779212.	2.2	35
1133	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. <i>Journal of Infectious Diseases</i> , 2022, 225, 777-784.	1.9	21

#	ARTICLE	IF	CITATIONS
1134	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
1135	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. <i>Vaccines</i> , 2021, 9, 1409.	2.1	22
1136	SARS-CoV-2 Targets and COVID-19 Vaccines. <i>Covid</i> , 2021, 1, 608-621.	0.7	4
1137	The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2) Tj ETQq1 1 0.784314 rgBT /Overl... Bluetongue Virus Challenge. <i>Journal of Virology</i> , 2022, 96, JVI0161421.	1.5	5
1138	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
1139	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	1.5	18
1140	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
1141	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
1142	Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost. <i>Frontiers in Immunology</i> , 2021, 12, 776933.	2.2	24
1144	ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination. <i>Neurological Sciences</i> , 2022, 43, 763-766.	0.9	19
1145	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
1146	Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. <i>Microbiology Spectrum</i> , 2021, 9, e0116221.	1.2	29
1147	Multicolor Flow Cytometry and High-Dimensional Data Analysis to Probe Complex Questions in Vaccinology. <i>Methods in Molecular Biology</i> , 2022, 2414, 433-447.	0.4	1
1148	Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. <i>Immuno</i> , 2021, 1, 442-456.	0.6	7
1149	Discussing the Efficacy and Safety of Covid-19 Vaccine Available in India- A Mini Review. <i>Shanghai Ligong Daxue Xuebao/Journal of University of Shanghai for Science and Technology</i> , 2021, 23, 330-343.	0.1	0
1150	COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation. <i>PLoS ONE</i> , 2021, 16, e0244415.	1.1	63
1151	Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies. <i>Diagnostics</i> , 2021, 11, 2193.	1.3	4
1152	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120

#	ARTICLE	IF	CITATIONS
1153	Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. <i>International Immunopharmacology</i> , 2021, 101, 108351.	1.7	36
1155	Current development in adenoviral vectors for cancer immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 571-581.	2.0	7
1156	A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. <i>EClinicalMedicine</i> , 2021, 42, 101218.	3.2	21
1157	Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. <i>Vaccines</i> , 2021, 9, 1375.	2.1	37
1158	From Genetics to Epigenetics: Top 4 Aspects for Improved SARS-CoV-2 Vaccine Designs as Paradigmatic Examples. <i>Global Medical Genetics</i> , 2022, 09, 014-017.	0.4	0
1161	Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. <i>Biotechnology Letters</i> , 2021, , 1.	1.1	13
1162	Previous COVID-19 Infection and Antibody Levels After Vaccination. <i>Frontiers in Public Health</i> , 2021, 9, 778243.	1.3	69
1163	Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates. <i>Human Gene Therapy</i> , 2022, 33, 275-289.	1.4	7
1164	Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103433.	0.9	26
1165	In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease. <i>Environmental Science and Pollution Research</i> , 2022, 29, 26775-26791.	2.7	5
1166	Research Progress in the Treatment of Complications and Sequelae of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 757605.	1.2	9
1167	Heterologous prime-boost strategies for COVID-19 vaccines. <i>Journal of Travel Medicine</i> , 2021, , .	1.4	37
1168	MAIT Cells in Respiratory Viral Infections in Mouse and Human. <i>Critical Reviews in Immunology</i> , 2021, 41, 19-35.	1.0	7
1169	Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. <i>Journal of Korean Medical Science</i> , 2021, 36, e311.	1.1	33
1170	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
1171	The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1172	An Excitation Wavelength-Optimized, Stable SERS Biosensing Nanoplatform for Analyzing Adenoviral and AstraZeneca COVID-19 Vaccination Efficacy Status Using Tear Samples of Vaccinated Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1173	Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 556-561.	0.6	12

#	ARTICLE	IF	CITATIONS
1174	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. <i>Cell Reports</i> , 2022, 38, 110210.	2.9	96
1176	Outcomes of patients with thromboembolic events following coronavirus disease 2019 AstraZeneca vaccination: a systematic review and meta-analysis. <i>Blood Coagulation and Fibrinolysis</i> , 2022, 33, 90-112.	0.5	14
1177	Relief After COVID-19 Vaccination: A Doubtful or Evident Outcome?. <i>Frontiers in Medicine</i> , 2021, 8, 800040.	1.2	3
1178	Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100154.	1.5	55
1179	COVID-19: Notes on its Etiology, Pathogenesis and Mediation. <i>Archives of Preventive Medicine</i> , 2020, , 045-057.	0.0	1
1180	O SARS-CoV-2 e a pr�tica odontol�gica. <i>Research, Society and Development</i> , 2020, 9, e751997884.	0.0	0
1181	Lessons from the COVID-19 Pandemic: Knowledge and Preventive Actions Among a Mexican Population Sample. <i>Archivos De Medicina</i> , 2020, 21, .	0.1	1
1182	Evidencia disponible sobre el abordaje terap�utico de pacientes con COVID-19: una revisi�n narrativa. <i>Ciencia, Tecnolog�a Y Salud</i> , 2020, 7, 363-380.	0.0	1
1183	Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110615.	0.5	10
1185	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. <i>Cell and Bioscience</i> , 2021, 11, 202.	2.1	13
1186	Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China. <i>Expert Review of Vaccines</i> , 2022, 21, 269-275.	2.0	1
1187	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
1188	Identification of Amino Acids within Nonstructural Proteins 10 and 14 of the Avian Coronavirus Infectious Bronchitis Virus That Result in Attenuation <i>In Vivo</i> and <i>In Ovo</i> . <i>Journal of Virology</i> , 2022, 96, jvi0205921.	1.5	9
1189	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	3.7	24
1190	Immunological challenges of the "new" infections: corona viruses. , 2022, , 395-450.		2
1191	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	2.2	19
1192	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Lancet Infectious Diseases</i> , The, 2022, 22, 636-648.	4.6	52
1193	Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. <i>Drugs and Therapy Perspectives</i> , 2022, 38, 1-9.	0.3	5



#	ARTICLE	IF	CITATIONS
1194	Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. <i>Public Health</i> , 2022, 205, 1-5.	1.4	2
1195	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e193-e202.	3.4	45
1197	Central retinal vein occlusion post-COVID-19 vaccination. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 308.	0.5	33
1198	Neutralization Assessments Reveal High Cardiothoracic Ratio and Old Age as Independent Predictors of Low Neutralizing Antibody Titers in Hemodialysis Patients Receiving a Single Dose of COVID-19 Vaccine. <i>Journal of Personalized Medicine</i> , 2022, 12, 68.	1.1	7
1199	Innovative vaccine approaches—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
1200	Survey of SARS-CoV-2 in dogs and cats in high-risk areas during the second wave of COVID-19 outbreak, Thailand. <i>Zoonoses and Public Health</i> , 2022, 69, 737-745.	0.9	19
1201	Dynamics of antibody response to CoronaVac vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 2139-2148.	2.5	33
1203	Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers. <i>Journal of Medical Virology</i> , 2022, 94, 2008-2018.	2.5	11
1205	Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. <i>Protein Engineering, Design and Selection</i> , 2022, 35, .	1.0	6
1206	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
1207	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
1208	To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review. <i>Egyptian Journal of Bronchology</i> , 2022, 16, .	0.3	1
1209	Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield) — A case report and review of literature. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 319.	0.5	16
1210	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
1211	COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study. <i>American Journal of Hematology</i> , 2022, 97, 470-480.	2.0	37
1212	Acute liver failure after vaccination against COVID-19; a case report and review literature. <i>Respiratory Medicine Case Reports</i> , 2022, 35, 101568.	0.2	10
1213	Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 734279.	2.2	5
1214	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). <i>BMC Infectious Diseases</i> , 2022, 22, 70.	1.3	4

#	ARTICLE	IF	CITATIONS
1215	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. <i>BMC Medicine</i> , 2022, 20, 29.	2.3	20
1216	ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India. <i>Current Drug Safety</i> , 2022, 17, 344-349.	0.3	3
1217	New-onset Adult-onset Still's disease-like syndrome after ChAdOx1 nCoV-19 vaccination—a case series with review of literature. <i>Clinical Rheumatology</i> , 2022, 41, 1569-1575.	1.0	22
1218	Socio-Demographic Characteristics of COVID-19 Vaccine Recipients in Kwara State, North Central Nigeria. <i>Frontiers in Public Health</i> , 2021, 9, 773998.	1.3	2
1219	Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis. <i>Vaccine</i> , 2022, 40, 587-593.	1.7	6
1220	COVID-19: Testing Landscape Post-Infection, -Vaccination, and Future Perspectives. <i>Viral Immunology</i> , 2022, 35, 5-14.	0.6	0
1221	Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. <i>Cureus</i> , 2022, 14, e21721.	0.2	4
1223	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. <i>EBioMedicine</i> , 2022, 75, 103762.	2.7	32
1224	Evaluating Correlates of Protection for Mix-Match Vaccine Against COVID-19 VOCs With Potential of Evading Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1225	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 250-259.	3.0	3
1227	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. <i>Vaccines</i> , 2022, 10, 160.	2.1	33
1228	Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. <i>Lancet</i> , The, 2022, 399, 25-35.	6.3	109
1229	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
1230	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. <i>Nature Communications</i> , 2022, 13, 462.	5.8	17
1231	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	2.7	104
1232	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	1.1	6
1233	Clinical characteristics and histopathology of COVID-19 related deaths in South African adults. <i>PLoS ONE</i> , 2022, 17, e0262179.	1.1	8
1234	Differential immunogenicity of homologous versus heterologous boost in Ad26.COVS vaccine recipients. <i>Med</i> , 2022, 3, 104-118.e4.	2.2	38

#	ARTICLE	IF	CITATIONS
1235	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2022, 17, e0260733.	1.1	60
1236	Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1070-1078.	0.6	9
1237	The T cell immune response against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 186-193.	7.0	785
1238	OS DESAFIOS DA SAÚDE DIGITAL NA PANDEMIA DE COVID-19: UMA REVISÃO INTEGRATIVA NO SCIELO. <i>Recisatec</i> , 2022, 2, e2182.	0.0	0
1239	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
1240	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses. <i>Frontiers in Medicine</i> , 2021, 8, 758118.	1.2	15
1241	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
1242	Post COVID-19 vaccine deaths - Singapore's early experience. <i>Forensic Science International</i> , 2022, 332, 111199.	1.3	9
1243	COVID-19 vaccine therapeutic trials review: published results and registered protocols. <i>Journal of Global Health Reports</i> , 0, 5, .	1.0	0
1245	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297
1247	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-16.	0.7	2
1248	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	1.5	225
1249	Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors. <i>Infection</i> , 2022, 50, 889-895.	2.3	6
1250	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2381-2392.	2.7	14
1251	The correlates of substance use among older adults in Ghana during the COVID-19 pandemic. <i>Journal of Global Health Reports</i> , 0, 6, .	1.0	1
1252	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. <i>Lancet Microbe</i> , The, 2022, 3, e173-e183.	3.4	31
1253	Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 601-608.	2.0	11
1254	Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262922.	1.1	10

#	ARTICLE	IF	CITATIONS
1255	Case Report: Hypergranular Platelets in Vaccine-Induced Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 824601.	1.1	2
1256	Biomimetic metal-organic frameworks as protective scaffolds for live-virus encapsulation and vaccine stabilization. <i>Acta Biomaterialia</i> , 2022, 142, 320-331.	4.1	19
1257	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
1258	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
1259	Peculiarities of the T Cell Immune Response in COVID-19. <i>Vaccines</i> , 2022, 10, 242.	2.1	24
1260	Prevalence of COVID-19 vaccine reactogenicity among Bangladeshi physicians. <i>FASEB BioAdvances</i> , 2022, 4, 379-390.	1.3	6
1261	A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. <i>Vaccine</i> , 2022, 40, 2068-2075.	1.7	17
1263	Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. <i>International Journal of Infectious Diseases</i> , 2022, 116, 204-209.	1.5	31
1264	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. <i>Clinical Biochemistry</i> , 2022, 101, 19-25.	0.8	5
1265	An excitation wavelength-optimized, stable SERS biosensing nanoplatfor for analyzing adenoviral and AstraZeneca COVID-19 vaccination efficacy status using tear samples of vaccinated individuals. <i>Biosensors and Bioelectronics</i> , 2022, 204, 114079.	5.3	11
1266	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, 146.	2.9	14
1267	The race for a COVID-19 vaccine: where are we up to?. <i>Expert Review of Vaccines</i> , 2022, 21, 355-376.	2.0	11
1268	Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5129-5132.	1.4	10
1273	Adults' Acceptance of COVID-19 Vaccine for Children in Selected Lower- and Middle-Income Countries. <i>Vaccines</i> , 2022, 10, 11.	2.1	22
1275	Cenários Pós-Pandemia para a Malha de P&D e para a Produção de Vacinas no Brasil. <i>Cadernos De Prospecção</i> , 2021, 14, 5.	0.0	0
1276	Optimal strategy for a dose-escalation vaccination against COVID-19 in refugee camps. <i>AIMS Mathematics</i> , 2022, 7, 9288-9310.	0.7	5
1278	Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1279	Safety and Immunogenicity of a Candidate Tuberculosis Vaccine ChAdOx1-85A Delivered by Aerosol Versus Intramuscular Route in Healthy Adults in a Phase 1, Double-Blind Randomized Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1280	Living in a Region With a Low Level of COVID-19 Infection: Health Belief Toward COVID-19 Vaccination and Intention to Receive a COVID-19 Vaccine in Hong Kong Individuals. <i>Inquiry (United States)</i> , 2022, 59, 004695802210827.	0.5	2
1281	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1283	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
1284	Predictors of COVID-19 Vaccine Acceptability among Patients Living with HIV in Northern Nigeria: A Mixed Methods Study. <i>Current HIV Research</i> , 2022, 20, 82-90.	0.2	14
1286	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210892.	1.0	21
1287	A longitudinal study to estimate adverse events following two doses of COVID-19 vaccination. <i>Medical Journal of Dr D Y Patil Vidyapeeth</i> , 2022, .	0.0	0
1288	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110566.	0.7	13
1289	Incidence of adverse reactions to COVID-19 vaccination: A meta-analysis of randomized controlled trials. <i>Journal of Acute Disease</i> , 2022, 11, 1.	0.0	0
1290	Cutaneous reactions to COVID-19 vaccines: A review. <i>JAAD International</i> , 2022, 7, 178-186.	1.1	24
1291	Fighting Fire with Fire: Immunogenicity of Viral Vected Vaccines against COVID-19. <i>Viruses</i> , 2022, 14, 380.	1.5	4
1292	E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. <i>Vaccines</i> , 2022, 10, 295.	2.1	2
1293	Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2188.	1.8	15
1294	Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccineâ€“A Study Protocol. <i>Frontiers in Medicine</i> , 2022, 9, 761655.	1.2	4
1295	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
1296	Innovation Opportunity and Challenge of Standardization in Response to COVID-19 Pandemic and the Socio-Economic Impact: A Case Study in Indonesia. <i>Standards</i> , 2022, 2, 66-82.	0.6	3
1297	Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection. <i>Thorax</i> , 2022, 77, 1229-1236.	2.7	7
1298	Exploring Data and Literature Currently Available on the COVID-19 Vaccines. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 7-12.	0.4	1
1299	The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection. <i>Vaccines</i> , 2022, 10, 338.	2.1	5

#	ARTICLE	IF	CITATIONS
1300	Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tests for Border Screening During the Very Early Phase of Coronavirus Disease 2019 Pandemic: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 748522.	1.2	2
1301	Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2392.	1.2	11
1302	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
1304	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. <i>Frontiers in Microbiology</i> , 2022, 13, 845316.	1.5	8
1305	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 142.	2.4	24
1306	Vocal fold paralysis following first dose of Oxford-AstraZeneca coronavirus disease 2019 vaccine. <i>Journal of Laryngology and Otology</i> , 2022, 136, 466-468.	0.4	4
1307	Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials. <i>BMJ Open</i> , 2022, 12, e050278.	0.8	21
1308	COVID-19 Vaccines: An Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 72.	1.6	32
1309	Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. <i>Vaccines</i> , 2022, 10, 277.	2.1	15
1310	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. <i>Frontiers in Immunology</i> , 2022, 13, 840707.	2.2	11
1311	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
1312	A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca. <i>Vaccines</i> , 2022, 10, 292.	2.1	5
1313	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5
1314	Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	1
1315	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. <i>Vaccines</i> , 2022, 10, 312.	2.1	3
1317	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. <i>Nature Computational Science</i> , 2022, 2, 123-131.	3.8	39
1318	Rare Side Effects After Inactivated Sars-Cov-2 Vaccine (Coronovac). <i>Konuralp Tip Dergisi</i> , 0, , .	0.1	0
1319	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. <i>Journal of Clinical Medicine</i> , 2022, 11, 1503.	1.0	4

#	ARTICLE	IF	CITATIONS
1320	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221.	0.6	13
1321	SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1511-1514.	0.6	3
1322	Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1244-1264.	1.9	17
1324	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
1325	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 845887.	2.2	13
1326	A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. <i>Dermatologic Therapy</i> , 2022, 35, e15461.	0.8	31
1327	Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	9
1328	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. <i>Emerging Microbes and Infections</i> , 2022, 11, 1058-1071.	3.0	63
1329	Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention. <i>BMC Geriatrics</i> , 2022, 22, 191.	1.1	7
1330	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. <i>Journal of Microbiology</i> , 2022, 60, 308-320.	1.3	6
1331	Evaluation of Adverse Effects in Nursing Mothers and Their Infants After COVID-19 mRNA Vaccination. <i>Breastfeeding Medicine</i> , 2022, 17, 412-421.	0.8	3
1333	Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity. <i>Journal of Infection</i> , 2022, 84, 658-667.	1.7	3
1335	Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center. <i>Journal of Infection and Public Health</i> , 2022, 15, 360-364.	1.9	1
1336	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1372-1381.	1.9	41
1337	Misuse of Antipyretic Amid Fear of COVID-19 Vaccine. <i>Journal of the Nepal Medical Association</i> , 2022, 60, 329-330.	0.1	0
1338	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	6
1339	miRNAs in SARS-CoV-2 Infection: An Update. <i>Current Drug Metabolism</i> , 2022, 23, .	0.7	2
1340	Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases. <i>BMJ Case Reports</i> , 2022, 15, e244638.	0.2	9

#	ARTICLE	IF	CITATIONS
1342	Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology. <i>View</i> , 2022, 3, .	2.7	8
1343	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
1344	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. <i>Nature Immunology</i> , 2022, 23, 768-780.	7.0	41
1345	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95.	1.5	3
1346	Side Effects of Mixing Vaccines against COVID-19 Infection among Saudi Population. <i>Vaccines</i> , 2022, 10, 519.	2.1	6
1347	COVID-19 vaccination in patients with immune thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 1637-1644.	2.5	30
1348	COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3111.	1.2	1
1349	Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study. <i>Vaccines</i> , 2022, 10, 400.	2.1	4
1350	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. <i>Npj Vaccines</i> , 2022, 7, 31.	2.9	21
1351	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. <i>Pathogens</i> , 2022, 11, 368.	1.2	23
1352	Probióticos “ uma espada ou um escudo no desfecho da COVID-19?. <i>Research, Society and Development</i> , 2022, 11, e11011427165.	0.0	0
1353	Covid-19 Vaccines Available in India. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2391-2397.	0.6	3
1354	Pandemic-response adenoviral vector and RNA vaccine manufacturing. <i>Npj Vaccines</i> , 2022, 7, 29.	2.9	12
1355	ChAdOx1 adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. <i>European Journal of Immunology</i> , 2022, 52, 936-945.	1.6	12
1357	Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, e0039622.	1.2	6
1358	A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2022, 77, 351-362.	0.6	7
1359	Oral SARS-CoV-2 Spike Protein Recombinant Yeast Candidate Prompts Specific Antibody and Gut Microbiota Reconstruction in Mice. <i>Frontiers in Microbiology</i> , 2022, 13, 792532.	1.5	11
1360	Proporción de la población con vacunación completa contra Covid-19 a nivel mundial. <i>Repertorio De Medicina Y Cirugia</i> , 0, , 14-18.	0.0	0



#	ARTICLE	IF	CITATIONS
1361	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
1362	Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. , 2022, 39, 89-97.		1
1363	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
1364	Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 228-237.	0.9	4
1365	mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People. <i>Viruses</i> , 2022, 14, 748.	1.5	11
1366	High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge. <i>Nature Communications</i> , 2022, 13, 1726.	5.8	5
1367	Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. <i>Future Microbiology</i> , 2022, 17, 417-424.	1.0	11
1368	Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2022, 10, 834.	1.4	16
1369	Grape Phytochemicals and Vitamin D in the Alleviation of Lung Disorders. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1276-1292.	0.6	6
1370	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
1371	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e252-e264.	3.4	29
1372	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8
1373	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-Covran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. <i>BMJ Open</i> , 2022, 12, e056872.	0.8	12
1374	IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study. <i>Vaccine</i> , 2022, 40, 2535-2539.	1.7	9
1375	A global survey in the developmental landscape of possible vaccination strategies for COVID-19. <i>Clinical Immunology</i> , 2022, 237, 108958.	1.4	11
1376	Identification of Recombinant Chimpanzee Adenovirus C68 Degradation Products Detected by AEX-HPLC. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 753481.	2.0	0
1378	Reprint of: Development of vaccines and vaccinal strategies against COVID-19: the information contributing to shared decision-making. <i>La Presse Médicale Open</i> , 2022, , 100024.	0.1	0
1379	Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 173-182.	1.5	13

#	ARTICLE	IF	CITATIONS
1380	Multifunctional role of exosomes in viral diseases: From transmission to diagnosis and therapy. <i>Cellular Signalling</i> , 2022, 94, 110325.	1.7	26
1381	Stroke Associated with COVID-19 Vaccines. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106440.	0.7	21
1382	Covaxin: An overview of its immunogenicity and safety trials in India. <i>Bioinformatics</i> , 2021, 17, 840-845.	0.2	9
1383	Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. <i>Vaccines</i> , 2021, 9, 1490.	2.1	48
1384	Case Report: Adult Onset Still's Disease after vaccination against Covid-19. <i>Wellcome Open Research</i> , 0, 6, 333.	0.9	3
1385	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
1386	Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers. <i>Vaccines</i> , 2022, 10, 54.	2.1	8
1388	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
1389	Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. <i>Vaccines</i> , 2021, 9, 1478.	2.1	5
1390	Vaccinations, Mobility and COVID-19 Transmission. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 97.	1.2	16
1391	Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV. <i>Journal of Infectious Diseases</i> , 2022, 225, 1937-1947.	1.9	9
1392	Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle. <i>Vaccines</i> , 2021, 9, 1473.	2.1	4
1393	Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 143-152.	0.6	5
1394	Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies. <i>Vaccines</i> , 2021, 9, 1471.	2.1	17
1396	Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. <i>GeroScience</i> , 2022, 44, 57-61.	2.1	3
1397	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. <i>Npj Vaccines</i> , 2021, 6, 151.	2.9	36
1398	Prevalence of SARS-CoV-2 antibodies in hospital employees, Central Germany. <i>Laboratoriums Medizin</i> , 2022, 46, 61-69.	0.1	0
1399	Cerebral venous sinus thrombosis related to vaccine-induced immune thrombotic thrombocytopenia: First reported case in Vietnam. <i>Tap Chi Nghien Cuu Y Hoc</i> , 2022, 148, 122-127.	0.0	0

#	ARTICLE	IF	CITATIONS
1400	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 123.	3.1	10
1401	Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization. <i>Viruses</i> , 2021, 13, 2440.	1.5	8
1403	Tháp±c trá°ing vÃ ká°jt quá°£ Ä'ía»u trá»« phá°£n vá»† sau tiÃ°m vá°c xin Astrazeneca phá°ng Covid-19 tá°ji TrÆ°á»ng Äá°ji há»c Y HÃ° Nghien Cuu Y Hoc, 2021, 147, 206-211.	0.0	0
1404	Venous Thrombosis and SARS-CoV-2. <i>Hamostaseologie</i> , 2022, 42, 240-247.	0.9	7
1405	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. <i>Cells</i> , 2022, 11, 67.	1.8	7
1406	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. <i>3 Biotech</i> , 2022, 12, 15.	1.1	20
1407	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
1408	Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 5081-5088.	1.2	11
1409	COVID-19 Vaccination in Children: An Open Question. <i>Current Pediatric Reviews</i> , 2022, 18, 226-236.	0.4	5
1410	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
1411	T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants. <i>Frontiers in Medicine</i> , 2021, 8, 793102.	1.2	21
1412	Retinal Hemorrhage after SARS-CoV-2 Vaccination. <i>Journal of Clinical Medicine</i> , 2021, 10, 5705.	1.0	23
1414	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. <i>Vaccines</i> , 2022, 10, 37.	2.1	15
1415	Modelling the Human Immune System Response to the ChAdOx1 nCoV-19 Vaccine. , 2021, , .		0
1416	Antibody Response to ChAdOx1-nCoV-19 Vaccine Among Recipients in Bangladesh: A Prospective Observational Study. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5491-5500.	1.1	12
1417	Disentangling post-vaccination symptoms from early COVID-19. <i>EClinicalMedicine</i> , 2021, 42, 101212.	3.2	8
1418	Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. <i>Age and Ageing</i> , 2022, 51, .	0.7	7
1419	Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RÎ³cKO.NOD) for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	6

#	ARTICLE	IF	CITATIONS
1420	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. <i>Science Translational Medicine</i> , 2022, 14, eabm2311.	5.8	100
1421	Analgesia and COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3543-3544.	1.1	1
1422	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
1423	Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre. <i>Indian Journal of Medical Microbiology</i> , 2022, 40, 200-203.	0.3	3
1424	Arterial Thrombosis in an Unusual Site (Ulnar Artery) after COVID-19 Vaccination – A Case Report. <i>Clinics and Practice</i> , 2022, 12, 237-242.	0.6	2
1425	Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems. <i>Pharmaceutics</i> , 2022, 14, 856.	2.0	4
1426	COVID-19 Vaccines: Current and Future Perspectives. <i>Vaccines</i> , 2022, 10, 608.	2.1	26
1427	The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study. <i>Biomedicines</i> , 2022, 10, 911.	1.4	9
1429	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170.	1.8	4
1444	Vaccination or NPI? A conjoint analysis of German citizens' preferences in the context of the COVID-19 pandemic. <i>European Journal of Health Economics</i> , 2023, 24, 39-52.	1.4	1
1445	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. <i>Inflammation</i> , 2022, 45, 1430-1449.	1.7	16
1446	Seroprevalence and dynamics of anti-SARS-CoV-2 antibody among healthcare workers following ChAdOx1 nCoV-19 vaccination. <i>Epidemiology and Infection</i> , 2022, 150, 1-20.	1.0	9
1447	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
1448	Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	14
1449	Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0267102.	1.1	15
1450	Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. <i>Cell Journal</i> , 2021, 23, 523-531.	0.2	4
1451	Plasma exchange as an effective salvage therapy in AZD1222 vaccine-induced thrombotic thrombocytopenia: a case report. <i>Blood Transfusion</i> , 2021, , .	0.3	1
1452	SARS-COV-2 – the pandemic of the XXI century, clinical manifestations – neurological implications. <i>Journal of Medicine and Life</i> , 2022, 15, 319-327.	0.4	2

#	ARTICLE	IF	CITATIONS
1453	Meso-scale Discovery Assay Detects the Changes of Plasma Cytokine Levels in Mice after Low or High LET Ionizing Irradiation. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 540-551.	0.2	3
1456	Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model. <i>Age and Ageing</i> , 2022, 51, .	0.7	6
1457	COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions. , 0, 2, .		7
1458	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
1459	Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12698.	1.0	8
1460	Serosurveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: prospective cohort study. <i>SeÅenovskij Vestnik</i> , 2021, 13, 14-23.	0.3	0
1462	Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort. <i>Neurology International</i> , 2022, 14, 406-416.	1.3	32
1463	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10
1464	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. <i>Vaccines</i> , 2022, 10, 712.	2.1	4
1465	Impact of bariatric surgery on the effectiveness of serological response after COVID-19 vaccination. <i>Langenbeck's Archives of Surgery</i> , 2022, , .	0.8	1
1466	Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 895209.	2.2	13
1467	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
1468	Case Report: Acute Necrotizing Encephalopathy Following COVID-19 Vaccine. <i>Frontiers in Neurology</i> , 2022, 13, 872734.	1.1	7
1469	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
1470	Amplifying Lateral Flow Assay Signals for Rapid Detection of COVID-19 Specific Antibodies. <i>Global Challenges</i> , 2022, 6, .	1.8	6
1471	Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac. <i>Vaccine</i> , 2022, 40, 3320-3329.	1.7	6
1472	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	2.1	15
1473	Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. <i>Vaccines</i> , 2022, 10, 754.	2.1	10

#	ARTICLE	IF	CITATIONS
1474	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
1475	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
1476	Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review. <i>Immunological Medicine</i> , 2022, 45, 225-237.	1.4	18
1477	Efficacy of COVID-19 vaccines by race and ethnicity. <i>Public Health</i> , 2022, , .	1.4	6
1478	COVID-19 vaccination challenges: A mini-review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	5
1479	Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months. <i>Frontiers in Immunology</i> , 2022, 13, 879036.	2.2	13
1480	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. <i>Journal of Hematology and Oncology</i> , 2022, 15, 54.	6.9	26
1481	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
1482	Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAEâ€”An Observational Study. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	50
1483	Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review. <i>Cureus</i> , 2022, , .	0.2	3
1484	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
1485	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq1 1 0.784314 rgBT <sup>3</sup> Overl	0.8	1
1486	Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. <i>Npj Vaccines</i> , 2022, 7, 50.	2.9	14
1487	Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	16
1488	A Review of Different Vaccines and Strategies to Combat COVID-19. <i>Vaccines</i> , 2022, 10, 737.	2.1	8
1489	Isolation of five different primary cell types from a single sample of human skin. <i>STAR Protocols</i> , 2022, 3, 101378.	0.5	1
1490	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
1491	Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population. <i>Npj Vaccines</i> , 2022, 7, 52.	2.9	9

#	ARTICLE	IF	CITATIONS
1493	Reactivación del virus varicela zoster tras vacunación contra la covid 19. Piel, 2022, , .	0.0	0
1494	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. The Lancet Regional Health - Western Pacific, 2022, 24, 100474.	1.3	13
1495	Structure-guided affinity maturation of a novel human antibody targeting the SARS-CoV-2 nucleocapsid protein. Scientific Reports, 2022, 12, 8469.	1.6	3
1496	Adverse effects following COVID-19 vaccination in Iran. BMC Infectious Diseases, 2022, 22, 476.	1.3	27
1497	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	0.4	2
1498	Anti-SARS-CoV-2 antibodies among vaccinated healthcare workers: Repeated cross-sectional study. Journal of Family Medicine and Primary Care, 2022, 11, 1883.	0.3	4
1500	Facial Angioedema after the first dose of Covishield (adenovirus-vectored severe acute respiratory) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Sociedade Brasileira De Medicina Tropical, 0, 55, .	0.4	1
1501	When and How Will the Epidemic of COVID-19 End?. , 2022, 13, 641.		4
1502	Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India. Journal of Family Medicine and Primary Care, 2022, 11, 2201.	0.3	2
1503	Immunological heterogeneity informs estimation of the durability of vaccine protection. Journal of the Royal Society Interface, 2022, 19, .	1.5	2
1504	Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer. Thrombosis Research, 2022, 213, S77-S83.	0.8	1
1506	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respiratory Medicine,the, 2022, 10, 749-760.	5.2	65
1507	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	13.5	105
1508	Viral vector vaccines. Current Opinion in Immunology, 2022, 77, 102210.	2.4	28
1509	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. Innovare Journal of Medical Sciences, 0, , 6-13.	0.2	0
1510	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant. Journal of Heart and Lung Transplantation, 2022, 41, 1417-1425.	0.3	10
1512	Use of adenovirus type-5 vector vaccines in COVID-19: potential implications for metabolic health?. Minerva Endocrinology, 2022, 47, .	0.6	5
1513	Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity. Scientific Reports, 2022, 12, .	1.6	12

#	ARTICLE	IF	CITATIONS
1514	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. <i>Journal of Molecular Medicine</i> , 2022, 100, 875-901.	1.7	8
1515	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
1516	Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	7
1517	Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study. <i>American Journal of Emergency Medicine</i> , 2022, 58, 154-158.	0.7	5
1518	Principles of SARS-CoV-2 glycosylation. <i>Current Opinion in Structural Biology</i> , 2022, 75, 102402.	2.6	27
1519	Hepatitis B Virus Infection Flare Induced Acute-on-chronic Liver Failure After COVID-19 Vaccination: A Case Report. <i>Hepatitis Monthly</i> , 2022, 21, .	0.1	2
1520	Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 500-505.	0.6	2
1521	HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 2769.	1.7	8
1522	mRNA or ChAdOx1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
1523	Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 20 years after allogeneic bone marrow transplant. <i>British Journal of Haematology</i> , 2022, 198, 668-679.	1.2	13
1524	Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 109, 108906.	1.7	43
1525	A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in cats. <i>Research in Veterinary Science</i> , 2022, 148, 52-64.	0.9	0
1526	Vaccine Development and Social Control. , 2021, 2, 93-124.		0
1527	Pivotal Immune-Bridging Study of the Inactivated Whole-Virus COVID-19 Vaccine VLA2001: A Phase 3, Randomized Controlled Clinical Trial in Adults Using Adenoviral Vector Vaccine AZD1222 as a Comparator. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1528	Adequacy of Hemodialysis Serves as an Independent Predictor of Humoral Response to ChAdOx1 Prime-Boost Vaccination in Hemodialysis Patients. <i>Viruses</i> , 2022, 14, 1149.	1.5	0
1529	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. <i>Molecular Immunology</i> , 2022, 149, 107-118.	1.0	2
1530	ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. <i>Vaccines</i> , 2022, 10, 959.	2.1	3
1532	Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation. <i>Vaccines</i> , 2022, 10, 960.	2.1	1



#	ARTICLE	IF	CITATIONS
1533	Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1534	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. <i>Nature Biotechnology</i> , 2022, 40, 1680-1689.	9.4	29
1535	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	24
1536	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6â€“17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 2212-2225.	6.3	23
1537	Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy. <i>Nature Cancer</i> , 2022, 3, 1039-1051.	5.7	12
1538	Polymerized porin as a novel delivery platform for coronavirus vaccine. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	1
1539	Case report of acute encephalitis following the AstraZeneca COVIDâ€“19 vaccine. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 950-956.	0.9	9
1540	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
1541	Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. <i>Hepatology</i> , 2023, 77, 1757-1772.	3.6	5
1542	Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
1543	Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1262.	1.5	1
1544	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
1545	Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. <i>Lancet Respiratory Medicine,the</i> , 2022, 10, 785-795.	5.2	15
1546	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2022, 7, 974-985.	5.9	30
1548	Vaccine Preventable Zoonotic Diseases: Challenges and Opportunities for Public Health Progress. <i>Vaccines</i> , 2022, 10, 993.	2.1	10
1549	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
1550	Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. <i>BMC Medicine</i> , 2022, 20, .	2.3	13
1551	Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. <i>Vaccines</i> , 2022, 10, 970.	2.1	6

#	ARTICLE	IF	CITATIONS
1552	Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine. <i>Vaccines</i> , 2022, 10, 929.	2.1	3
1553	Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. <i>Immunological Reviews</i> , 2022, 310, 27-46.	2.8	137
1555	The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. <i>Journal of Pharmacy Practice</i> , 2023, 36, 953-966.	0.5	6
1556	COVID-19 Vaccines and Autoimmune Hematologic Disorders. <i>Vaccines</i> , 2022, 10, 961.	2.1	23
1557	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
1558	Global emergence of Enterovirus 71: a systematic review. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, .	0.8	23
1559	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	1.7	9
1560	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. <i>Vaccine</i> , 2022, 40, 4220-4230.	1.7	27
1561	SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up. <i>Vaccine: X</i> , 2022, 11, 100175.	0.9	5
1562	Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review. <i>Journal of the Neurological Sciences</i> , 2022, 439, 120327.	0.3	16
1563	Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle. <i>Journal of Inorganic Biochemistry</i> , 2022, 234, 111899.	1.5	7
1564	Bionanomaterials for diagnosis and therapy of SARS-CoV-2. , 2022, , 469-489.		0
1565	Biopharmaceuticals for prevention of COVID-19: A scoping review. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022, 15, 245.	0.4	2
1566	Development of novel vaccines using nanomaterials against COVID-19. , 2022, , 329-345.		0
1567	COVID-19 vaccination: Is it a matter of concern?. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2431.	0.3	1
1569	Commentary on "Risk of venous thromboembolism after COVID-19 vaccination". <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1562-1564.	1.9	0
1570	Comparison of COVID-19 Vaccines Introduced in Korea. <i>Biomedical Science Letters</i> , 2022, 28, 67-82.	0.0	1
1571	Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 369-392.	0.5	9

#	ARTICLE	IF	CITATIONS
1572	Vaccine innovation model: A technology transfer perspective in pandemic contexts. <i>Vaccine</i> , 2022, 40, 4748-4763.	1.7	5
1573	Myths about diversity in clinical trials reduce return on investment for industry. <i>Nature Medicine</i> , 2022, 28, 1520-1522.	15.2	6
1575	Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022056.	0.5	1
1576	Vacunaci3n contra SARS-COV-2: efectos secundarios de la vacuna CHADOX1NCOV-19 (AstraZeneca). <i>Sapienza: International Journal of Interdisciplinary Studies</i> , 2022, 3, 183-193.	0.0	0
1577	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. <i>Emerging Microbes and Infections</i> , 2022, 11, 1890-1899.	3.0	12
1578	Will Peptides Help to Stop COVID-19?. <i>Biochemistry (Moscow)</i> , 2022, 87, 590-604.	0.7	1
1579	CASE REPORT OF BELLâ€™S PALSY FOLLOWING SECOND DOSE OF COVISHIELD VACCINE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 1-2.	0.3	1
1580	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	23
1581	Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals. <i>AIDS Research and Therapy</i> , 2022, 19, .	0.7	20
1582	Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. <i>Science Advances</i> , 2022, 8, .	4.7	68
1583	Experiences and perspectives of cancer stakeholders regarding COVIDâ€™19 vaccination. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 234-242.	0.7	4
1584	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
1586	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134.	1.7	10
1587	Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	7
1588	Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1873-1881.	2.0	4
1590	Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19â€™BNT162b2 mRNA Vaccination. <i>Viruses</i> , 2022, 14, 1470.	1.5	5
1591	The use of viral vectors in vaccine development. <i>Npj Vaccines</i> , 2022, 7, .	2.9	73
1592	Reactions in leprosy patients triggered by COVIDâ€™19 vaccination â€™ a crossâ€™sectional study from a tertiary care centre in India. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	5

#	ARTICLE	IF	CITATIONS
1593	Recurrence of thrombotic thrombocytopenic purpura after vaccination with mRNA-1273 COVID-19 vaccine. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 81-85.	0.4	4
1594	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 122, 793-801.	1.5	17
1595	COVID-19 vaccination in people with multiple sclerosis, real-life experience. <i>Clinical Neurology and Neurosurgery</i> , 2022, 220, 107374.	0.6	6
1596	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	2.0	12
1597	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
1598	Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. <i>Infectious Disease Reports</i> , 2022, 14, 537-546.	1.5	23
1599	Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine. <i>BMJ Case Reports</i> , 2022, 15, e250913.	0.2	3
1600	Why does COVID-19 continue to spread despite mass vaccination?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1601	Acute Adverse Effects of Vaccines Against SARS-COV-2. <i>Cureus</i> , 2022, , .	0.2	3
1602	Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. <i>Lancet Microbe</i> , The, 2022, 3, e663-e671.	3.4	12
1603	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. <i>EClinicalMedicine</i> , 2022, 51, 101569.	3.2	58
1604	Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin. <i>Vaccines</i> , 2022, 10, 1226.	2.1	0
1605	Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
1607	Case Report: Subacute thyroiditis after receiving inactivated SARS-CoV-2 vaccine (BBIBP-CorV). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1608	Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1609	A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
1612	Severe autoimmune haemolytic anaemia following SARS-CoV-2 vaccination in patients with treatment naïve B-cell neoplasms: a case series. <i>Pathology</i> , 2022, , .	0.3	2
1613	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6

#	ARTICLE	IF	CITATIONS
1614	Surveillance of adverse events associated with 145 000 doses of COVID-19 vaccines in a Brazilian municipality. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2022, 46, 1.	0.6	0
1615	Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. <i>Vaccine</i> , 2022, 40, 5701-5708.	1.7	0
1616	Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1619-1629.	15.2	56
1617	Current Vaccine Platforms in Enhancing T-Cell Response. <i>Vaccines</i> , 2022, 10, 1367.	2.1	8
1618	Effects of boosted mRNA and adenoviralâ€¢vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 5713-5722.	2.5	23
1619	Thermal stabilization of diverse biologics using reversible hydrogels. <i>Science Advances</i> , 2022, 8, .	4.7	9
1620	Acute Polyserositis with Cardiac Tamponade and Bilateral Refractory Pleural Effusion after ChAdOx1 nCoV-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1286.	2.1	1
1621	Plasma metabolome and cytokine profile reveal glycyproline modulating antibody fading in convalescent COVID-19 patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
1623	A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects. <i>Recent Patents on Nanotechnology</i> , 2022, 16, .	0.7	0
1624	Integrase deficient lentiviral vector: prospects for safe clinical applications. <i>PeerJ</i> , 0, 10, e13704.	0.9	6
1625	A Temperature-Sensitive Recombinant of Avian Coronavirus Infectious Bronchitis Virus Provides Complete Protection against Homologous Challenge. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
1626	Indoxyl Sulfate Alters the Humoral Response of the ChAdOx1 COVID-19 Vaccine in Hemodialysis Patients. <i>Vaccines</i> , 2022, 10, 1378.	2.1	1
1627	Detection of Short-Term Side Effects of ChAdOx1 nCoV-19 Vaccine: A Cross-Sectional Study in a War-Torn Country. <i>Journal of Pragmatic and Observational Research</i> , 0, Volume 13, 85-91.	1.1	4
1628	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
1629	Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross-sectional survey in Northwest Ethiopia. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
1631	Efficacy and safety of COVIDâ€¢19 vaccines: A network metaâ€¢analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
1632	Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
1633	The epitranscriptome of Vero cells infected with SARS-CoV-2 assessed by direct RNA sequencing reveals m6A pattern changes and DRACH motif biases in viral and cellular RNAs. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3

#	ARTICLE	IF	CITATIONS
1634	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
1635	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. <i>Med</i> , 2022, 3, 760-773.e5.	2.2	13
1636	Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis. <i>Vaccines</i> , 2022, 10, 1366.	2.1	4
1637	Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1638	A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. <i>F1000Research</i> , 0, 11, 909.	0.8	0
1639	Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2. <i>Molecular Therapy</i> , 2022, 30, 3639-3657.	3.7	6
1640	Comparison of replicating and nonreplicating vaccines against SARS-CoV-2. <i>Science Advances</i> , 2022, 8, .	4.7	6
1641	A platform technology for generating subunit vaccines against diverse viral pathogens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1642	Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study. <i>Current Drug Safety</i> , 2023, 18, 516-527.	0.3	2
1643	Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study. <i>EClinicalMedicine</i> , 2022, 52, 101608.	3.2	8
1644	Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. <i>Computational Biology and Chemistry</i> , 2022, 101, 107754.	1.1	7
1645	Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study. <i>Digestive Diseases and Sciences</i> , 2023, 68, 676-684.	1.1	6
1647	Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study. <i>Lancet Regional Health - Europe</i> , The, 2022, 21, 100478.	3.0	10
1648	Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. <i>EBioMedicine</i> , 2022, 84, 104264.	2.7	4
1649	Prevention and management of adverse events following COVID-19 vaccination using traditional Korean medicine: An online survey of public health doctors. <i>World Journal of Clinical Cases</i> , 0, 10, 10053-10065.	0.3	5
1650	COVID-19: Vaccines and therapeutics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128987.	1.0	4
1651	Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population. <i>Public Health in Practice</i> , 2022, 4, 100313.	0.7	1
1653	Active surveillance of adverse events following the first dose of COVID-19 vaccination “Oxford” AstraZeneca (Covishield) vaccine. <i>Saudi Journal for Health Sciences</i> , 2022, 11, 104.	0.1	0

#	ARTICLE	IF	CITATIONS
1654	Hazards of vaccinating the way out of Covid-19 pandemic: Study of adverse events following immunization (Aefi) in India. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, .	0.0	0
1655	COVID-19, influenza, and other acute respiratory viral infections: etiology, immunopathogenesis, diagnosis, and treatment. Part 2. Other acute respiratory viral infections. Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia, 2022, 40, 3.	0.1	0
1656	Acceptance of covid-19 vaccine among the healthcare providers in India. Journal of Family Medicine and Primary Care, 2022, 11, 3465.	0.3	0
1657	Development of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) Vaccines. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2022, 31, 484.	0.0	0
1658	Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. Infection and Chemotherapy, 2022, 54, 504.	1.0	2
1659	Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals. Indian Journal of Medical Research, 2022, .	0.4	1
1660	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	2
1661	Enhancing Neutralizing Antibodies Against Receptor Binding Domain of SARS-CoV-2 by a Safe Natural Adjuvant System. SSRN Electronic Journal, 0, , .	0.4	0
1662	Application of Lysine-Based Peptide Dendrimers For Gene Delivery: A Functional Transfection In Vitro. SSRN Electronic Journal, 0, , .	0.4	0
1663	Vaccine History: From Smallpox to Covid-19. Engineering Materials, 2022, , 519-543.	0.3	0
1664	A review on COVID-19 vaccinations. Biomedical and Biotechnology Research Journal, 2022, 6, 50.	0.3	6
1665	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Frontiers in Microbiology, 0, 13, .	1.5	14
1667	Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation. Viruses, 2022, 14, 1916.	1.5	7
1668	Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021. Journal of the Formosan Medical Association, 2022, 121, 2438-2445.	0.8	4
1669	Case Report: Adult Onset Still's Disease after vaccination against Covid-19. Wellcome Open Research, 0, 6, 333.	0.9	2
1671	Fear of COVID-19 among employees of large companies and vaccination against COVID-19 - a cross-sectional study (Silesia, Poland). Journal of Education, Health and Sport, 2022, 12, .	0.0	1
1672	New insights into human immune memory from SARS-CoV-2 infection and vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 0, , .	2.7	5
1673	Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota. World Journal of Clinical Infectious Diseases, 0, 12, 50-60.	0.5	0

#	ARTICLE	IF	CITATIONS
1674	T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 1494.	2.1	6
1675	Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis. <i>PLoS ONE</i> , 2022, 17, e0273676.	1.1	5
1676	Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1678	Postvaccinal GABA $\beta$ receptor antibody encephalitis after ChAdOx1 nCoV-19 vaccination. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1673-1678.	1.7	4
1680	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. <i>Infectious Diseases</i> , 0, , .	4.0	0
1682	Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1683	Struktur Biomolekul dan Mekanisme Aksi Vaksin Sars-Cov-2 Efektif dalam Melawan Covid-19. , 2022, 2, 1-10.		0
1686	Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	1
1687	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. <i>DARU, Journal of Pharmaceutical Sciences</i> , 0, , .	0.9	5
1688	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1689	Sinopharm $\text{\textcircled{TM}}$ s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1462.	2.1	5
1690	The Silver Lining of the COVID-19 Pandemic: Fast-Tracked Vaccine Production and Approval. , 0, , .		0
1693	Immunological imprint on peripheral blood in kidney transplant recipients after two doses of SARS-CoV-2 mRNA vaccination in Japan. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1694	Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
1695	Gene Therapy Cargoes Based on Viral Vector Delivery. <i>Current Gene Therapy</i> , 2023, 23, 111-134.	0.9	5
1696	A critical overview of current progress for COVID-19: development of vaccines, antiviral $\text{\textcircled{A}}$ drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
1697	The Post-Vaccination Quantitative Total Immunoglobulin Levels against SARS-CoV-2 in Healthcare Workers: A Multi-Centric Cohort Study in India. <i>Vaccines</i> , 2022, 10, 1535.	2.1	0
1698	Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. <i>Rheumatology</i> , 2023, 62, 1445-1450.	0.9	9



#	ARTICLE	IF	CITATIONS
1700	Development of variantâ€proof severe acute respiratory syndrome coronavirus 2, panâ€sarbecovirus, and panâ€coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
1702	Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. <i>Journal of Biological Chemistry</i> , 2022, 298, 102442.	1.6	2
1703	Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, 201-209.	2.9	10
1704	Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELDâ„¢ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1705	New vector and vaccine platforms: mRNA, DNA, viral vectors. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 338-344.	1.5	7
1706	No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19. <i>Vaccine: X</i> , 2022, 12, 100224.	0.9	2
1708	Â¿Las vacunas anti-COVID-19 disponibles se diferencian en eficacia en personas mayores?. <i>Revista Del Hospital Italiano De Buenos Aires</i> , 2021, 41, .	0.0	0
1709	Cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine. <i>Indian Journal of Medical Specialities</i> , 2022, 13, 263.	0.1	1
1710	Adjuvants to increase immunogenicity of SARS-CoV-2 RBD and support maternalâ€fetal transference of antibodies in mice. <i>Pathogens and Disease</i> , 2022, 80, .	0.8	1
1711	The use of adenoviral vectors in gene therapy and vaccine approaches. <i>Genetics and Molecular Biology</i> , 2022, 45, .	0.6	3
1712	Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco). <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211336.	1.0	2
1713	Persistent Antigen Harbored by Alveolar Macrophages Enhances the Maintenance of Lung-Resident Memory CD8+ T Cells. <i>Journal of Immunology</i> , 2022, 209, 1778-1787.	0.4	7
1714	Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
1716	Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study. <i>Vaccines</i> , 2022, 10, 1706.	2.1	3
1717	Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. <i>Nature Medicine</i> , 2023, 29, 147-157.	15.2	32
1718	Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. <i>EBioMedicine</i> , 2022, 85, 104298.	2.7	70
1719	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
1720	Episomes and Transposasesâ€Utilities to Maintain Transgene Expression from Nonviral Vectors. <i>Genes</i> , 2022, 13, 1872.	1.0	0

#	ARTICLE	IF	CITATIONS
1722	Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel. <i>Vaccines</i> , 2022, 10, 1797.	2.1	2
1723	Efficacy and safety of four COVID-19 vaccines in preventing SARS-CoV-2 infection: A rapid review. <i>Biomedica</i> , 2022, 42, 19-31.	0.3	2
1724	Dose optimisation and scarce resource allocation: two sides of the same coin. <i>BMJ Open</i> , 2022, 12, e063436.	0.8	5
1725	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
1726	Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1727	Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	5
1728	Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling. <i>Vaccine</i> , 2022, 40, 7032-7041.	1.7	4
1730	Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity. <i>Vaccines</i> , 2022, 10, 1708.	2.1	3
1731	Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses. <i>Vaccines</i> , 2022, 10, 1805.	2.1	3
1732	Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. <i>Genes</i> , 2022, 13, 1941.	1.0	3
1734	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1735	Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study. <i>Brain Sciences</i> , 2022, 12, 1396.	1.1	2
1736	In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1737	Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
1738	Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population. <i>Vaccines</i> , 2022, 10, 1781.	2.1	17
1740	Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 10-18.	0.6	5
1741	Spontaneous Subarachnoid Haemorrhage After COVID-19 Vaccination; a Rare Case Report. <i>Archives of Clinical Infectious Diseases</i> , 2022, 17, .	0.1	0
1742	Pandemic vaccines: a formidable challenge for pharmacovigilance. <i>Nature Reviews Drug Discovery</i> , 0, , .	21.5	0

#	ARTICLE	IF	CITATIONS
1743	SEMI-QUANTITATIVE ANALYSIS OF SARS-COV-2 IGG ANTIBODIES FOLLOWING CHADOX1-NCOV (COVISHIELD <sup>®</sup> ) VACCINATION. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 155-158.	0.3	0
1744	Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (<sc>SARS-CoV-2): A follow-up study. <i>European Journal of Neurology</i> , 2023, 30, 463-473.	1.7	12
1745	Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. <i>IScience</i> , 2022, 25, 105412.	1.9	8
1746	Anti-PF4 antibodies associated with disease severity in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
1747	Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity. <i>Vaccine</i> , 2022, 40, 6864-6872.	1.7	1
1748	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. <i>IScience</i> , 2022, 25, 105379.	1.9	4
1750	COVID-19 vaccination: Immune response in healthcare workers—A study with review of literature. <i>Indian Journal of Pathology and Microbiology</i> , 2022, .	0.1	0
1751	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. <i>Vaccines</i> , 2022, 10, 1924.	2.1	8
1752	Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. <i>Biomedicines</i> , 2022, 10, 2892.	1.4	4
1753	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. <i>Science Immunology</i> , 2022, 7, .	5.6	42
1754	Dual activation profile of monocytes is associated with protection in Mexican patients during SARS-CoV-2 disease. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 7905-7916.	1.7	1
1755	Insights into the Structural Complexities of SARS-CoV-2 for Therapeutic and Vaccine Development. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, 1945-1959.	0.6	0
1756	Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1757	A survey of mechanisms underlying current and potential <sc>COVID-19 vaccines. <i>Apmis</i> , 0, , .	0.9	0
1758	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1759	Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100845.	3.3	6
1760	COVID-19 vaccination in patients with cancer: Opportunities and challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1761	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5

#	ARTICLE	IF	CITATIONS
1762	Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets. <i>Npj Vaccines</i> , 2022, 7, .	2.9	0
1764	Determinants of Participation in Immunization Against COVID-19 Before Vaccine Distribution in Iran. <i>Shiraz E Medical Journal</i> , 2022, 23, .	0.1	0
1765	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
1766	Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2023, 32, 106860.	0.7	3
1767	Psychological factors associated with reporting side effects following COVID-19 vaccination: A prospective cohort study (CoVAccS “Wave 3). <i>Journal of Psychosomatic Research</i> , 2023, 164, 111104.	1.2	3
1768	Cellular assays to evaluate B-cell function. <i>Journal of Immunological Methods</i> , 2023, 512, 113395.	0.6	0
1769	Ethnological aspects of COVID-19. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0
1770	COVID-19 vaccines: Update of the vaccines in use and under development. <i>Vacunas (English Edition)</i> , 2022, 23, S88-S102.	0.3	0
1771	COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part 2. Other Acute Respiratory Viral Infections. <i>Molecular Genetics, Microbiology and Virology</i> , 2022, 37, 107-116.	0.0	0
1772	T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa. <i>Aids</i> , 2023, 37, 105-112.	1.0	4
1773	Presentations at the UK National Immunisation Conference. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
1775	Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2-Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	3
1776	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1777	A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. <i>F1000Research</i> , 0, 11, 909.	0.8	1
1778	Innovative approaches in transforming <sc>microRNAs</sc> into therapeutic tools. <i>Wiley Interdisciplinary Reviews RNA</i> , 2023, 14, .	3.2	18
1779	Six Months Follow-Up Study on Health Care Workers on Persistence of Antibodies to SARS-CoV-2 after Covishield Vaccination. <i>Journal of Evolution of Medical and Dental Sciences</i> , 0, , 884-887.	0.1	0
1780	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
1781	COVID-19 Vaccination Is Associated with a Better Outcome in Acute Ischemic Stroke Patients: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6878.	1.0	3

#	ARTICLE	IF	CITATIONS
1782	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1783	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
1785	A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales. <i>Vaccine</i> , 2023, 41, 511-518.	1.7	3
1786	A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
1787	Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report. <i>Vaccines</i> , 2023, 11, 5.	2.1	5
1788	The Effect of COVID-19 Vaccines on Stroke Outcomes: A Single-Center Study. <i>World Neurosurgery</i> , 2023, 170, e834-e839.	0.7	2
1789	Effect of inactivated COVID-19 vaccines on seizure frequency in patients with epilepsy: A multicenter, prospective study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1790	Adenovirus vector system: construction, history and therapeutic applications. <i>BioTechniques</i> , 2022, 73, 297-305.	0.8	23
1791	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. <i>Expert Review of Vaccines</i> , 2023, 22, 35-53.	2.0	8
1792	Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes. <i>Communications Biology</i> , 2022, 5, .	2.0	0
1793	Understanding the Attitudes and Willingness of Adult Chinese Patients with Rheumatic Diseases Towards COVID-19 Vaccination. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 2269-2281.	1.2	1
1794	Protease-Independent Production of Poliovirus Virus-like Particles in <i>Pichia pastoris</i> : Implications for Efficient Vaccine Development and Insights into Capsid Assembly. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	2
1795	A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Reports</i> , 2023, 42, 111903.	2.9	34
1796	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
1797	AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. <i>Cell Reports Medicine</i> , 2023, 4, 100882.	3.3	10
1798	Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. <i>IScience</i> , 2022, 25, 105649.	1.9	7
1799	Dressing Bacteria With a Hybrid Immunoactive Nanosurface to Elicit Dual Anticancer and Antiviral Immunity. <i>Advanced Materials</i> , 2023, 35, .	11.1	21
1800	Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors. <i>ELife</i> , 0, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
1801	COVID-19 vaccines and a perspective on Africa. Trends in Immunology, 2023, 44, 172-187.	2.9	4
1802	COVID-19 and hepatic injury: Diversity and risk assessment. World Journal of Gastroenterology, 0, 29, 425-449.	1.4	5
1803	Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults. Clinical and Experimental Immunology, 0, , .	1.1	1
1804	COVID vaccines inciting lepra reaction: An observation in a referral centre. , 0, 3, 11.		0
1806	IFN- $\gamma$ -Based ELISpot as a New Tool to Detect Human Infections with Borna Disease Virus 1 (BoDV-1): A Pilot Study. Viruses, 2023, 15, 194.	1.5	5
1807	Beyond adaptive immunity: induction of trained immunity by COVID-19 adenoviral vaccines. Journal of Clinical Investigation, 2023, 133, .	3.9	3
1808	Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. Frontiers in Immunology, 0, 13, .	2.2	1
1809	One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer Journal, 2023, 13, .	2.8	16
1810	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	2.1	14
1811	COVID-19 Vaccinesâ€”All You Want to Know. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 143-172.	0.8	4
1812	COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. EClinicalMedicine, 2023, 56, 101823.	3.2	12
1813	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. International Journal of Infectious Diseases, 2023, 128, 112-120.	1.5	6
1814	Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 361-381.	0.2	2
1815	Durability of ChAdOx1 nCoV-19 (Covishield <sup>Â</sup> ) Vaccine Induced Antibody Response in Health Care Workers. Vaccines, 2023, 11, 84.	2.1	3
1816	Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE). BMJ Open, 2022, 12, e069065.	0.8	5
1818	Evaluation of healthcare workers first vaccinated with COVID-19 vaccine in Northwest Syria Observations of vaccine side effects in emergency departments. Genel T $\pm$ p Dergisi, 0, , .	0.1	0
1819	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology, 2023, 12, 177.	1.3	11
1820	Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 56, .	0.4	2

#	ARTICLE	IF	CITATIONS
1821	Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity. <i>Engineering</i> , 2023, 27, 127-139.	3.2	0
1822	Cohort event monitoring for safety signal detection in adult individuals 18 years and above after immunisation with coronavirus disease 2019 vaccines in Nigeria. <i>Nigerian postgraduate medical journal, The</i> , 2023, 30, 18.	0.1	0
1823	Bioactivity prospection, antimicrobial, nutraceutical, and pharmacological potentialities of <i>Carica papaya</i> . , 2023, , 587-606.		0
1824	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	14
1825	Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 161-174.	1.1	6
1826	Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1827	Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. <i>American Journal of Gastroenterology</i> , 2023, 118, 1388-1394.	0.2	3
1828	Corneal Allograft Endothelial Rejection after Sinopharm COVID-19 Vaccination; Report of Six Cases. <i>Seminars in Ophthalmology</i> , 2023, 38, 565-571.	0.8	2
1829	Establishment of a neutralization assay for Nipah virus using a high-titer pseudovirus system. <i>Biotechnology Letters</i> , 2023, 45, 489-498.	1.1	1
1830	Assessment of potential risk factors for COVID-19 among health care workers in a health care setting in Delhi, India -a cohort study. <i>PLoS ONE</i> , 2023, 18, e0265290.	1.1	1
1831	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0
1832	Effects of coronavirus disease 2019 vaccination on seizures in patients with epilepsy. <i>Chinese Medical Journal</i> , 2023, 136, 571-577.	0.9	0
1833	Side Effects of COVID-19 Vaccines Among Diabetic Subjects and Healthy Individuals. <i>Cureus</i> , 2023, , .	0.2	5
1834	Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2 seropositive individuals. , 2023, 2, 100083.		2
1835	Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. <i>International Immunopharmacology</i> , 2023, 118, 109998.	1.7	1
1836	Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. <i>Journal of Pharmacological Sciences</i> , 2023, 152, 1-21.	1.1	7
1837	Evaluation and comparison of four quantitative SARS-CoV-2 serological assays in COVID-19 patients and immunized healthy individuals, cancer patients, and patients with immunosuppressive therapy. <i>Clinical Biochemistry</i> , 2023, 116, 1-6.	0.8	3
1838	The Vaccines Induced Autoimmunity. , 2022, , 19-55.		0

#	ARTICLE	IF	CITATIONS
1839	Role of vaccine in fighting the variants of COVID-19. Chaos, Solitons and Fractals, 2023, 168, 113159.	2.5	2
1840	Enhancing neutralizing antibodies against receptor binding domain of SARS-CoV-2 by a safe natural adjuvant system. Virus Research, 2023, 326, 199047.	1.1	0
1841	Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerging Infectious Diseases, 2023, 29, 381-388.	2.0	42
1842	Vaccine Design Strategies: Pathogens to Genomes. , 2021, , 440-488.		0
1843	Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials. Clinical and Experimental Immunology, 2023, 211, 280-287.	1.1	2
1844	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. Pathogens, 2023, 12, 244.	1.2	8
1845	Evaluation of the risk of SARS-CoV-2 infection and hospitalization in vaccinated and previously infected subjects based on real world data. Scientific Reports, 2023, 13, .	1.6	1
1846	Bilateral Persistent Placoid Maculopathy Following COVID-19 Vaccines: Real or Coincidence?. Ocular Immunology and Inflammation, 0, , 1-6.	1.0	1
1847	Assesment of specific T-cell immunity to SARS-CoV-2 virus antigens in COVID-19 reconvalescents. Voprosy Virusologii, 2023, 67, 527-537.	0.1	1
1848	Biological Controls and Standards for the Study and Control of Infectious Diseases. , 2023, , 21-34.		0
1849	The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination. Frontiers in Medicine, 0, 10, .	1.2	2
1850	Impact of COVID-19 on Cardiovascular Disease. Viruses, 2023, 15, 508.	1.5	15
1851	Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19. Npj Vaccines, 2023, 8, .	2.9	2
1852	Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccines. Pharmacological Research, 2023, 189, 106699.	3.1	1
1853	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 2023, 11, 432.	2.1	17
1854	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell Reports Medicine, 2023, 4, 100971.	3.3	4
1855	Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1. Vaccines, 2023, 11, 467.	2.1	1
1856	SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses, 2023, 15, 558.	1.5	1



#	ARTICLE	IF	CITATIONS
1857	Evaluation of QuantiFERON SARS-CoV-2 interferon- $\gamma$ release assay following SARS-CoV-2 infection and vaccination. <i>Clinical and Experimental Immunology</i> , 2023, 212, 249-261.	1.1	8
1858	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
1859	Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice. <i>Microbial Cell Factories</i> , 2023, 22, .	1.9	2
1860	Parainfluenza virus 5 is a next-generation vaccine vector for human infectious pathogens. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1861	Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
1862	Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations. <i>Vaccines</i> , 2023, 11, 564.	2.1	1
1863	The Coming of Age of Nucleic Acid Vaccines during COVID-19. <i>MSystems</i> , 2023, 8, .	1.7	5
1866	SAFETY MONITORING OF COVID-19 VACCINE: IN A TERTIARY CARE HOSPITAL IN HARYANA. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 35-37.	0.3	0
1867	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5011.	1.8	1
1868	Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5104.	1.8	2
1869	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4796.	1.2	2
1870	Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. <i>Npj Vaccines</i> , 2023, 8, .	2.9	13
1871	Exposure of low-temperature plasma after vaccination in tongue promotes systemic IgM induction against spike protein of SARS-CoV-2. <i>Free Radical Research</i> , 2023, 57, 30-37.	1.5	0
1872	Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1873	Identification of dynamic gene expression profiles during sequential vaccination with ChAdOx1/BNT162b2 using machine learning methods. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
1874	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. <i>Vaccines</i> , 2023, 11, 682.	2.1	7
1877	Open Questions over the COVID-19 Pandemic. , 2023, 1, 210-220.		0
1878	Assessment and Correlation of Adverse Events Following Coronavirus Disease Vaccination with Blood Group and Dietary Style. <i>Journal of the Scientific Society</i> , 2023, 50, 61.	0.1	0

#	ARTICLE	IF	CITATIONS
1880	IMPORTÂNCIA DA CONSCIENTIZAÃ‡O DA VACINAÃ‡O CONTRA COVID-19 NO BRASIL. Revista SaÃºde Multidisciplinar, 2023, 14, .	0.1	1
1881	Dendrimer-Mediated Delivery of DNA and RNA Vaccines. <i>Pharmaceutics</i> , 2023, 15, 1106.	2.0	7
1882	Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity. <i>Vaccines</i> , 2023, 11, 784.	2.1	0
1884	Implications of potential clinically relevant interactions between COVID-19 vaccines and concomitant medications. <i>Reviews in Medical Virology</i> , 0, , .	3.9	0
1885	Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
1886	Immunisation with purified <i>Coxiella burnetii</i> phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines. <i>Vaccine</i> , 2023, 41, 3047-3057.	1.7	3
1887	COVID-19 Vaccine-Related Headache. <i>Headache</i> , 2023, , 77-86.	0.2	0
1888	COVID-19 outbreakâ€™ journey of dental care workers: A systematic review. <i>National Journal of Maxillofacial Surgery</i> , 2023, 14, 16.	0.1	0
1889	Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. <i>Nature Communications</i> , 2023, 14, .	5.8	7
1902	A profound perception into manifestation of lifesaver. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1917	Therapeutic Interventions for COVID-19. , 0, , .		0
1920	Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity. <i>International Review of Cell and Molecular Biology</i> , 2023, , 43-86.	1.6	1
1925	Infection Control, Prophylaxis, and Vaccinations in Hematopoietic Cell Transplantation Recipients. , 2024, , 413-428.		0
1943	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	2.8	13
1954	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
1957	Nephrotic syndrome following COVID-19 vaccination: a systematic review. <i>Journal of Nephrology</i> , 2023, 36, 2431-2440.	0.9	1
1965	How close are we to a new, effective tuberculosis vaccine? Recent advances in the field. , 2023, , 164-177.		0
1981	Ibuprofen, other NSAIDs and COVID-19: a narrative review. <i>Inflammopharmacology</i> , 2023, 31, 2147-2159.	1.9	2

#	ARTICLE	IF	CITATIONS
1994	New-onset aplastic anemia after SARS-CoV-2 vaccination. International Journal of Hematology, 0, , .	0.7	0
2010	A Review of COVID-19 Vaccines, Immunogenicity, Safety, and Efficacy Toward Addressing Vaccine Hesitancy, Inequity, and Future Epidemic Preparedness. , 0, , .		0
2017	Cutaneous Reactions to Non-mRNA COVID-19 Vaccines. Updates in Clinical Dermatology, 2023, , 31-40.	0.1	0